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FOREWORD 
Galectin-1 is a protein involved in different facets of tumour progression. This 
thesis analyses the impact of galectin-1 as a target for therapy of neuroblastoma, 
the most common extracranial solid cancer in childhood. It also focuses on the use 
of novel therapies and animal models in preclinical investigations of galectin-1 
downregulation that could possibly contribute to improve the current poor survival 
of patients with the most aggressive relapsing form of the disease.  
 
Essen, January 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Let me tell you the secret that has led me to my goal.  
 My strength lies solely in my tenacity 
     Louis Pasteur
 4 
 
TABLE OF CONTENTS 
 
1. INTRODUCTION……………………………………………………………………...7 
1.1. Neuroblastoma………………………………………………………………..7 
1.1.1 Biology of Neuroblastoma………………………………………..7 
1.1.2 Clinical Presentation, Diagnosis and Staging………………….8 
1.2 Targeted Treatment of Neuroblastoma: An Overview…………………..12 
1.2.1. Histone Deactylase Inhibitors…………………………………..14 
1.2.1.1. Suberoylanilide hydroxamic acid........................15 
1.2.1.2. Valproic Acid......................................................15 
1.2.2. Temozolomide……………………………………………………15  
1.2.3. Farnesylthiosalicylic Acid……………………………………….16 
1.3. Mouse Models of Neuroblastoma………………………………………..16 
1.3.1. Xenograft Models………………………………………………………17 
1.3.2. Orthotopic Metastatic Models…………………………………………17 
1.3.3. Transgenic Models……………………………………………………..18 
1.4. Galectin-1…………………………………………………………………..19 
1.5. Objectives…………………………………………………………………..23 
2. MATERIALS AND METHODS…………………………………………………….24 
2.1.   Materials…………………………………………………………………….24 
2.1.1. Chemicals and Consumables…………………………………..24 
2.1.2. Buffers and Reagents………………………………………...…26 
2.1.3. List of Primers and Oligonucleotide Sequences……………..27 
2.1.4. Enzymes………………………………………………………….28 
2.1.5. Commercial Kits………………………………………………….28 
2.1.6. Antibodies………………………………………………………...29 
2.1.7. Cell Culture Materials……………………………………………29 
2.1.7.1 Medium for Bacteria Cell Culture……………….29 
2.1.7.2 Bacteria Strain and their Characteristics………30 
2.1.7.3 Neuroblastoma Cell Lines and their  
 Origins………………………………………….....30 
2.1.8. Equipment………………………………………………………...30 
2.1.9. Surgical Equipment……...…………………………………….....31 
 
Introduction 
5 
 
2.2.   Methods……………………………………………………………………..32 
2.2.1 Cell Cultures……………………………………………………..32 
2.2.2 Drug Formulation and Administration………………....………32 
2.2.3 Proliferation/cytotoxicity Assay..………………………………..32 
2.2.3.1 MTT Proliferation Assay…………………………33 
2.2.3.2 xCELLigence Cellular Analysis…………………33 
2.2.4 shRNA  Regulated Galectin-1 Expression....………………….33 
2.2.5 siRNA Transfection……………………………………………...34 
2.2.6 Reversed Transcriptase PCR Analysis………………………..34 
2.2.7 Co-Immunoprecipitation………………………………………...35 
2.2.8 Western Analysis.....................................................................35 
2.2.9 Cell Cycle Analysis by Flow Cytometry………………………...36 
2.3. Animal Experiments…………………………………………………………36 
2.3.1 Ethics and Animal Care……………………………………….…36 
2.3.2 Microsurgical Procedure………………………………………...36 
2.3.3 Mouse Grafting and Treatment Schedules…………………....37 
2.3.4 Histology…………………………………………………………..37 
2.3.5 Immunohistochemistry…………………………………………..37 
2.3.6 Statistical Analysis……………………………………………….38 
3. RESULTS…………………………………………………………………………….39 
3.1.   Transient siRNA/shRNA Directed Galectin-1 Downregulation………..39 
3.2. Histone Deacetylase Inhibitors Inhibit Proliferation of  
Neuroblastoma Cells in vitro....................................................................42 
3.3. Effects of Farnesylthiosalicylic Acid and Temozolomide on 
Neuroblastoma Cell Growth in vitro….….................................................45 
3.4. Effects of Combining Temozolomide to Farnesylthosalicylic  
Acid in Neuroblastoma Cells in vitro……………………………………....46 
3.5. Galectin-1 Co-localises with HRas in Neuroblastoma Cells…………....52 
3.6. Galectin-1 Silencing in Neuroblastoma does not apparently  
Potentiate the Anti-proliferative Activity of HDAC Inhibitors,  
FTS or TMZ in vitro……………..…………………………………………..53 
3.7. The Anti-proliferative effect of Galectin-1 Downregulation is not 
Accompanied by Changes in Cell Cycle Distribution…………………..63 
Introduction 
6 
 
3.8. Steps Towards an Orthotopic Neuroblastoma Tumour Model…………65 
3.9. FTS does not Show Antitumour Activity as a Single Agent but 
Chemosensitises Experimental Neuroblastoma to the  
Effects of TMZ……………………………………………………………….67 
3.10. TMZ or Galectin-1 Downregulation Increase the Survival of  
Neuroblastoma Tumour-bearing Mice but do not act 
synegistically………………………………………………………………..69 
3.11. The Tumour Growth Inhibitory Effect of TMZ and Galectin-1  
Silencing is not Primarily Caused by Reduced Cell 
Proliferation…………………………………………………………………71 
 
4. DISCUSSION………………………………………………………………………..73 
4.1. In Vitro Studies………………………………………………………………74 
4.2. HDAC Inhibitors and Galectin-1 Silencing……………………………….75 
4.3. TMZ, FTS And Galectin-1 Silencing in vitro and in vivo………………...76 
5. CONCLUSION………………………………………………………………………80 
6. REFERENCES………………………………………………………………………81 
7. APPENDIX…………………………………………………………………………...98 
8. ACKNOWLEDGMENTS………………………………………..…………………100 
9. CURRICULUM VITAE…………………………………………………………….102
Introduction 
7 
 
1. INTRODUCTION 
 
1.1. NEUROBLASTOMA 
Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second 
most common extracranial malignant tumour of childhood and the most common 
solid tumour of infancy (Park et al., 2008). It was first described by the German 
physician Rudolf Virchow in 1864 and later named by James Homer Wright in 
1910. Ever since, neuroblastoma has continued to bewitch paediatric oncologists 
due to its enigmatic clinical behaviour. On the lower end of the scale, the tumour 
will undergo spontaneous regression or differentiation to a more benign tumour 
with very minimal or no therapy whereas on the extreme end, the tumours 
progress or relapse despite aggressive multimodality therapy.   
The incidence rate of neuroblastoma is 10.5 cases per million children who are 
less than 15 years old (Park et al., 2008). It accounts for about 8 - 10% of all 
childhood cancers and for 15 % of childhood cancer mortality and is reported to be 
the second most common cause of death in children only preceded by accidents 
(Maris, 2007; Castel et al., 2007). The incidence of Neuroblastoma is similar 
across the world with boys showing a slightly higher frequency than girls. Only 
speculations have been put forward for this discrepancy. 
1.1.1. Biology of Neuroblastoma 
Neuroblastoma arises from neural crest cells which is a pluripotent highly 
migratory cell population that arises at the junction of the neural tube and the 
dorsal ectoderm. The neural crest cells differentiate into a variety of cell types 
derivatives which include the peripheral nervous system, chromaffin (endocrine) 
cells of the adrenal medulla and paraganglia, pericytes, pigment cells and the 
facial skeleton (Park et al., 2008; Mora & Gerald, 2004). Neuroblastoma can arise 
anywhere along the sympathetic nervous system but 65 % of primary tumours 
arise in the abdomen with the medulla of the adrenal gland being predominant 
(Park et al., 2008).  
The aetiology of neuroblastoma is still mainly unknown, but environmental factors 
seem unlikely (Brodeur, 2003). Familial forms of NB are rare, accounting for about 
10 % of all cases. Recently, the anaplastic lymphoma kinase (ALK) was identified 
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as a predisposing factor for familiar neuroblastoma (Mosse et al., 2008) and has 
also shown to be mutated in sporadic neuroblastomas (Caren et al., 2008). 
Activating germline and somatic mutation in ALK was found as well as 
amplification and in-gene rearrangements, all which correlated to more advanced 
disease (Caren et al., 2008; Mosse et al., 2008). 
NB can also occur in patients affected with other neural crest disorders or 
malignancies, such as the heritable disease neurofibromatosis (von 
Recklinghausen disease), where neurofibromatous tumours develop, and 
Hirschsprung disease, with loss of ganglia in the colon, are associated with 
neuroblastoma (Brodeur, 2003, Park et al., 2008). In addition, a germline mutation 
and constitutional mutations in the PHOX2B gene has been shown to correlate 
with hereditary or multifocal NB (Bourdeaut et al., 2005; Van Limpt et al., 2003). 
This gene is also the major disease gene for congenital central hypoventilation 
disorder (Ondine’s Curse, a lack of autonomic respiratory control) which shows a 
hereditary co-occurrence with both neuroblastoma and Hirschsprung disease 
(Bourdeaut et al., 2005). Interestingly, there seems to be an under representation 
of neuroblastoma among patient with Downs Syndrome (Brodeur, 2003).  
 
1.1.2 Clinical Presentation, Diagnosis and Staging 
The clinical presentation of neuroblastoma is as heterogeneous as the tumour and 
depends upon the site of tumour origin, metastatic spread and the presence of 
paraneoplastic syndromes (Maris et al., 2007). The spectrum of pediatric neuro-
ectodermal tumours ranges from undifferentiated, truly malignant neuroblastomas, 
via ganglioneuroblastomas to well-differentiated, mostly benign ganglioneuromas 
(van Noesel & Versteeg, 2003). The current diagnosis for neuroblastoma is 
defined by histological presence of tumour cells in biopsy of bone marrow aspirate, 
assessment of catecholamines or catecholamine metabolites in urine or serum, 
and possible metastatic spread and tumour size is monitored by computer 
tomography, magnetic resonance imaging and/or scintigraphy (Maris et al., 2007; 
Park et al., 2008). 
At the time of diagnosis neuroblastoma is staged according to the international 
neuroblastoma staging system (INSS) (Brodeur et al., 2004), staging 1-4 (Table 
1). The most prognostic features in neuroblastoma are age, stage and tumour 
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biology (Brodeur et al., 1997; Schimada et al., 1999). Children aged < 18 months 
and are at a lower stage have a more favourable outlook than older infants and 
those at a higher stage with the exception of stage 4S (S = special). 
The INSS is a surgically based staging system, and as such patients with 
locoregional disease can vary significantly based on degree of surgical resection 
which is dependent on the skill of the surgeon that decides how extensive the 
excision can be thereby increasing the risk for staging patients more towards high-
risk treatment, hence the risk of over treating patients is also increased. In 
addition, patients with localised disease who will not undergo surgery cannot be 
properly staged. Given these limitations, the International Neuroblastoma Risk 
Group (INRG) addressed this problem in 2009 with a new staging system which is 
based on Image Defined Risk Factors (IDRF) that strictly evaluates the 
resectability. In this system the patients are divided into three stages, localised L1 
or L2 depending on if the tumours have IDRF or not, metastatic stage M and the 
special metastatic stage MS (Monclair et al., 2009). The INRG stage is then further 
weighed into the INRG classification system together with other prognostic factors 
to achieve a pre-treatment risk stratification system (Cohn et al., 2009). In the MS 
stage, that was previously called 4S, infant patients present with small localised 
tumours and metastases to the liver, skin and/or bone marrow. This is the group 
with in which there is spontaneous tumour regression.  
Five to ten percent of NBs that are detected regress without treatment, which is 
the highest frequency observed in any tumour type. Clinically, regression of NB 
can be manifested as a complete disappearance of the tumour or differentiation 
into a benign ganglioneuroma. Relapse may develop following spontaneous 
regression, but is considered a rare event (Haas et al., 1988).  
A consistent pattern of biological factors that describes these patients has not 
been established, although low MYCN levels and high TrkA expression are 
considered favourable. The three current hypotheses on the mechanism of 
regression are that it is due to an immunological attack on the tumour, 
spontaneous differentiation/maturation, or that there is a delay in the 
developmental time-switch for apoptosis (Papac, 1996; Hellstrom & Hellstrom, 
1971; Cole, 1981; Pritchard & Hickman, 1994). This intriguing clinical behaviour of 
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NB has stimulated research on differentiation- and apoptosis-inducing agents for 
the treatment of the disease. 
 
 
Table 1: International Neuroblastoma Staging System (INSS) [Brodeur et al, 1993] 
Stage 1 Localised tumour with complete gross excision with or without 
microscopic residual disease; representative ipsilateral lymph nodes 
negative for tumour microscopically (nodes attached to and removed 
with the primary tumour may be positive) 
Stage 2A Localised tumour with incomplete gross resection; representative 
ipsilateral nonadherent lymph nodes negative for tumour 
microscopically 
Stage 2B Localised tumour with or without complete gross excision with 
ipsilateral nonadherent lymph nodes positive for tumour; enlarged 
contralateral lymph nodes must be negative microscopically 
Stage 3 Unresectable unilateral tumour infiltrating across the midlinea
Stage 4 
, with or 
without regional lymph node involvement, localised unilateral tumour 
with contralateral regional lymph node involvement, or midline tumour 
with bilateral extension by infiltration (unresectable) or by lymph node 
involvement 
Any primary tumour with dissemination to distant lymph nodes, bone, 
bone marrow, liver, skin, or other organs (except as defined for stage 
4S) 
4S Localised primary tumour (as defined for stage 1, 2A, or 2B) with 
dissemination limited to skin, liver, or bone marrowb
 
 (limited to infants 
< 1 year of age) 
                                                            
a The midline is defined as the vertebral column. Tumours originating on one side and crossing the midline 
must infiltrate to or beyond the opposite side of the vertebral column. 
bMarrow involvement in stage 4S should be minimal (i.e. < 10% of total nucleated cells identified as 
malignant on bone marrow biopsy or marrow aspirate). More extensive marrow involvement should be 
considered to be stage 4. The metaiodobenzylguandine scan (if performed should be negative in the 
marrow). 
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The biological hallmark of neuroblastoma is the complexity of the genetic 
alterations. These can be used as biological markers independently of clinical 
features (reviewed in Bown 2001). There has been no single genetic change 
common to all neuroblastomas identified till date. However, there are several types 
of specific chromosomal abnormalities frequently associated with neuroblastoma 
such as, deletion of genetic material at chromosome arms 1p, 11q, and 14q, gain 
of genetic material at 17q and MYCN amplification. Furthermore, it has been 
shown that ploidy is a strong prognostic marker (Look et al., 1984). Triploid (3n) 
tumours are associated with low stage disease in younger children with favourable 
outcome, whereas diploid (2n) and tetraploid (4n) tumours are associated with 
unfavourable prognostic markers such as MYCN amplification and 1p deletion, 
and poor outcome (Hayashi et al., 1989; Kaneko et al., 1987; Look et al, 1991). 
The importance of the short arm of chromosome 1 (1p) in neuroblastoma genetics 
was identified in 1977 (Brodeur et al., 1977). Since then, other cytogenetic studies 
have confirmed the high frequency of deletions and other rearrangements of 1p 
(Gilbert et al., 1982). It was subsequently established that loss of 1p in 
neuroblastoma tumours correlated with unresectable and metastatic disease, 
whereas localised and clinically favourable tumours had an intact chromosome 1 
(Caron et al., 1996; Franke et al., 1986). Furthermore, it was shown that 
chromosome 1p deletion was associated with MYCN amplification, where 62% of 
neuroblastoma tumours with loss of heterozygosity (LOH) were MYCN amplified 
compared to 3% of tumours with intact chromosome 1p (Fong et al., 1989). The 
occurrence of chromosome 17q abnormalities in neuroblastoma was first 
described in 1984 (Gilbert et al., 1984). Later it was shown, that in most 
neuroblastoma cell lines and primary tumours with 1p deletions, the lost 1p 
material was replaced by a part of the long arm of chromosome 17 (17q) (Caron et 
al., 1994; Savelyeva et al., 1994; Van Roy et al., 1994). Gain of chromosome 17q 
has been associated with unfavourable prognosis in neuroblastoma (Abel et al., 
1999; Bown et al., 1999; Caron 1995; Lastowska et al., 1997). However, it is 
discussed that co-occurence with loss of 1p might account for this association and 
that 17q gain is not an independent prognostic marker. 
Amplification of the proto-oncogene MYCN is the most prototypic genetic 
aberration in neuroblastomas and is found in 20–25% of all neuroblastomas and 
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usually results in 5-400 gene copies per cell corresponding with high levels of 
protein expression (Seeger et al., 1988; Brodeur & Fong, 1989). MYCN was 
identified as a gene homologous to c-MYC and overrepresented in 
neuroblastomas (Schwab et al., 1983). 
MYCN amplification is associated with advanced disease as well as with an 
unfavorable prognosis in infants with a lower stage of disease (Brodeur et al., 
1984; Seeger et al., 1985) and further correlates with resistance to certain 
treatment modalities (Livingstone & Mairs, 1997) and the association appears to 
be independent of clinical stage (Nakagawara et al., 1987; Seeger et al., 1985) 
and age (Rubie et al., 1997). Therefore, MYCN status is usually assessed in 
patients due to its strong prognostic value and is used worldwide for treatment 
stratification (Berthold et al., 1997).  
Neurotrophin receptors represent another important factor responsible for 
regulating the malignant transformation of NB cells. Neurotrophin signalling plays 
a central role in normal neuronal development and is mediated by the Trk family of 
tyrosine kinases (Barbacid, 1995). Expression patterns of the neurotrophin 
receptors (TrkA, TrkB and TrkC) correlate with the biological and clinical features 
of NB and the degree of neuroblast differentiation (Brodeur et al., 1997). TrkA is 
the cognate receptor for the nerve growth factor (NGF), and developing neurons 
tend to differentiate in response to the ligand or die by apoptosis when NGF is 
withdrawn (characteristics of a dependence receptor). Consequently, high TrkA 
expression is correlated with a favourable prognosis of NB and is also inversely 
correlated to MYCN-amplification, and virtually absent in high-risk patients (Kogner 
et al, 1993; Nakagawara et al., 1993; Brodeur et al., 2009). By contrast, full length 
TrkB, the receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-
4, is highly expressed in MYCN-amplified advanced-stage aggressive tumours and 
is thought to mediate autocrine survival in tumours which simultaneously express 
BDNF (Nakagawara et al., 1994). 
 
1.2. Targeted Treatment of Neuroblastoma: An Overview 
In recent years, treatment protocols for neuroblastoma have been directed based 
on ‘risk-group’ criteria, which take into consideration various biological predictors 
of tumour behaviour (Table 2). In treating the low-risk patients, surgery is used as 
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the primary approach in order to minimize the risk of chemotherapy-related 
morbidity (Kushner et al., 1996). The survival rate for these patients is 95% 
(Alvarado et al, 2000; Perez et al., 2000). Stage 4S patients constitute a special 
group of patients who often undergo spontaneous regression in the majority of 
cases and also have a low risk of progression to advanced-stage disease, thus 
these patients are observed rather than operated (Nickerson et al., 2000). 
Intermediate-risk patients usually undergo surgery followed by moderate-dose 
multimodal chemotherapy. It has been shown that children lacking MYCN 
amplification had a 93% 3-year event-free survival (EFS) rate while children with 
MYCN amplification only had a 10% 3-year EFS rate, again pointing at the clinical 
significance of this marker (Schmidt et al., 2000). The majority of NB patients 
belong to the high-risk-group. Treatment for high-risk patients can be divided into 
four phases: 1) induction therapy (chemotherapy); 2) Local control maintenance 
using a combination of aggressive surgical resection and administration of 
radiotherapy 3) consolidation therapy (myeloablative chemotherapy and stem cell 
rescue (e.g. autologous bone marrow transplantation (ABMT)) and; 4) minimal 
residual disease therapy (e.g. administration of retinoids or targeted molecules 
directed against GD2 on NB cells (see below)). Up to date, the standard treatment 
for children with high-risk NB is intensive myeloablative therapy supported by 
autologous hematopoietic stem-cell transplantation and the administration of 
retinoids (this follow-up therapy might be long and might include immune therapy). 
The overall survival has improved for high-risk NB patients over the last decades, 
but cure rates remain low (10-20% long-term survival) despite intensive 
multimodal therapy (Brodeur & Maris, 2002). Given that conventional 
chemotherapeutics are nearing their maximum potential with regards to efficacy 
and patient tolerance, a myriad of novel therapeutic approaches have been 
investigated over the past several years. The identification of new active agents or 
drug combinations is essential to improving the prognosis for these patients.  
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Table 2: Neuroblastoma risk groups based on clinical and biological features 
(Brodeur, 2003) 
Stage Low Intermediate High 
1 All None None 
2A,B <1 year, or 1–21 years 
and MYCN non-Amp, 
or 1–21 years and 
MYCN Amp, FH 
None 1-21 years with MYCN 
Amp with UH 
3 None <1 year and MYCN 
non-Amp, or 1–21 
years and MYCN 
non-Amp with FH 
0–21 years and 
MYCN Amp, or 1–21 
years and MYCN non-
Amp with UH 
4 None < 1 year and MYCN 
non-Amp 
<1 year and MYCN 
Amp, or 1–21 years 
4S MYCN non-Amp; FH; 
hyperploid 
MYCN non-Amp; 
UH; diploid 
MYCN Amp 
Amp, amplified; FH, favorable histology; UH, unfavorable histology  
 
 
1.2.1. Histone Deacetylase Inhibitors 
Modulation of gene expression through targeting epigenetic events with DNA 
methyltransferase inhibitors and histone deacetylase (HDAC) inhibitors is one of 
the emerging strategies in cancer therapy and has demonstrated significant 
clinical activity in hematological malignancies. HDACIs have been shown to exert 
potent anticancer activities inducing differentiation, cell cycle arrest, apoptosis 
increase immunogenicity and inhibition of angiogenesis of cultured cancer cells. 
Notably, a high efficacy of these drugs has been selectively revealed in malignant 
cells rather than in normal cells (Emmanuelle et al., 2008). Histone deacetylase 
agents have also shown preclinical activity against neuroblastoma (Deubzer et al., 
2007, Furchert et al., 2007). A handful of HDACi are now being tested in phase I/II 
clinical trials both as monotherapy and in combination with other chemotherapeutic 
regiments and radiotherapy. 
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1.2.1.1. Suberoylanilide hydroxamic acid (SAHA) 
SAHA (vorinostat, Zolinza®) has already been approved as a second line 
treatment for patients with refractory, persistent or relapsed cutaneous T Cell 
Lymphoma. Clinical investigations have provided evidence that SAHA exhibits a 
high therapeutic potential for different forms of tumours at doses that are well 
tolerated by patients (Kelly et al., 2005). In addition, SAHA seems to exert 
antitumour effects in a synergistic manner with various compounds such as 
anticancer drugs (Ocker et al., 2005; Dey, 2006). 
 
1.2.1.2. Valproic acid (VPA) 
Valproic acid is now an established drug for the treatment of epileptic seizures 
(absence, tonic-clonic [grand mal]), and complex partial seizures) and mania in 
bipolar disorder (Bowden and Singh, 2005). VPA has shown potent antitumour 
effects in a variety of in vitro and in vivo systems, by modulating multiple pathways 
including cell cycle arrest, apoptosis, angiogenesis, metastasis, differentiation and 
senescence. These effects seem to be cell type specific which may depend also 
on the level of differentiation and the underlying genetic alterations. VPA has 
demonstrated strong anti cancer activity in NB studies (Cinatl et al., 1996; 
Michealis et al., 2004; Blaheta et al., 2007). 
 
1.2.2. Temozolomide (TMZ) 
TMZ is a second generation methylating imidazotetrazine compound (TZC) which 
undergoes chemical degradation at physiological pH to the cytotoxic metabolite 3-
methyl- (triazen-1-yl)imidazole-4-carboxamide (MTIC) (Tsang et al, 1991). TMZ 
was approved by the Food and Drug Administration (FDA) in the US, as well as in 
Europe, for the treatment of anaplastic astrocytoma and other high grade gliomas 
in an adjuvant setting. Several studies with TMZ have been recently completed in 
paediatric malignancies and other tumour entities (De Sol et al., 2006). 
Temozolomide is considered to exert its toxic effects primarily by generating O6-
methylguanine in DNA (Tisdale et al., 1987; Wedge et al., 1996). Quite recently, a 
phase II clinical trial of Irinotecan and Temozolomide in children with relapsed or 
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refractory NB showed the clinical benefit in these patients. Several studies in other 
cancers have revealed that TMZ is a pro-autophagic and anti-angiogenic drug. 
 
1.2.3. Farnesylthiosalicylic Acid (FTS) 
FTS, Salirasib (S-trans, trans-farnesylthiosalicylic acid), is a Ras farnesylcysteine 
mimetic that has been shown to selectively disrupt the association of active Ras 
proteins with the plasma membrane, imparing Ras membrane anchorage and 
function. FTS was shown to efficiently diminish Ras signaling (by disrupting 
galectin-1-HRAS association) and attenuation of cell growth in vitro and in vivo in 
various human malignancies including pancreatic, lung and other cancers (Rotblat 
et al., 2008). Phase I clinical studies have been carried out on solid tumours and 
phase II trials including a Phase I/II study dosing salirasib + gemcitabine for the 
treatment of newly diagnosed pancreatic cancer patients at Memorial Sloan-
Kettering as well as a Phase II trial treating both treatment naïve and previously 
treated lung cancer patients with salirasib mono-therapy are currently be carried 
out (Tsimberidou et al., 2009). Evidence of the antitumour activity of FTS in NB 
demonstrates that it causes NB growth arrest by disrupting the cooperation 
between Ras and MYCN (Yaari et al., 2005). 
 
1.3. MOUSE MODELS OF NEUROBLASTOMA 
The limited number of patients, which are currently often enrolled simultaneously 
in both national and international studies for the treatment of paediatric 
malignancies, poses a challenge as how to use these as wisely as possible (Ablett 
et al., 2004). In addition, as the cure rates in childhood cancer increase the 
number of available patients shrinks, and the eligible patients are often heavily 
pretreated so that the majority of them are not responding to chemotherapy (Balis 
et al., 2009). Modelling human cancer in animals is a field under constant 
development, and as much as these models can aid us both in unravelling the 
pathogenesis of the disease and aid in selection of therapies, there are drawbacks 
and considerations to be taken into consideration. These models may not be 
perfect in every aspect mimicking the patient child, but it is the best replacement 
available. 
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1.3.1. Xenograft Models 
In this model system, any type of tumour tissue (primary or cell lines) of any origin 
is implanted, usually s.c., in immunodeficient mice or rats, and after latency period 
growing tumours are established and the animals can be assigned to treatment 
schedules (Morton et al., 2007). The cells can be chosen to mimic a specific 
feature of the disease or a subgroup of the patients. For instance, Keratoepithelin 
was overexpressed in NB cell lines and implanted in nude mice to monitor tumour 
progression (Becker et al., 2006). The s.c. neuroblastoma xenografts have been 
the base for a wealth of publications and testing of conventional and novel 
therapies, and it is beyond the scope of this text to make a synoptic review of this 
subject. 
 
1.3.2. Orthotopic and Metastatic Models 
Orthotopic growth, meaning in its “right place”, has been described for several 
cancer types, and can provide additional valuable data in parallel or in addition to 
s.c. xenografts. Metastatic models have their further use in the fact that they 
represent the principal clinical challenge, i.e. eradicating disseminated disease.  
For neuroblastoma, the orthotopic sites used are in and around the adrenal gland, 
whilst metastatic models are reported with by i.v. injection (peripheral or into the 
aorta). In addition, orthotopic models can also metastasize (something s.c. 
xenografts very rarely do) especially in an NK-cell deficient model.  
The orthotopic neuroblastoma model was first described in 1994/95 (Flickinger et 
al., 1994; Judware et al., 1995). In 2000 it was further developed by GFP-
expressing cells (implanted near the adrenal gland), enabling the metastases to be 
detected by RT-PCR and the visualisation and measuring of the tumour by 
magnetic resonance imaging (MRI) (Moats et al., 2000). In 2001, a metastatic 
neuroblastoma model was described, where cells injected i.v. resulted in the 
development of both a primary adrenal mass and distant metastases to bone and 
liver (Engler et al., 2001). In an attempt to address the differences between 
heterotopic s.c. tumours and orthotopic tumours, a study in 2002 found that the 
orthotopic tumours showed more relevant biology (Khanna et al., 2002). In 2005, 
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orthotopic growth of neuroblastoma cells in the adrenal gland pointed out the 
importance of a correct microenvironment, as these tumours reproduced the 
abnormal vascularisation and metastatic growth of patients (Joseph et al., 2005). 
The orthotopic and metastatic model have the same practical requirements as the 
heterotopic model as they also use immunodeficient mice, except in syngeneic 
models. The use of non-invasive techniques to follow and measure tumour growth 
and disease dissemination is a requirement. 
 
1.3.3. Transgenic Models 
The earliest report of a transgenic model of neuroblastoma was in the early 90s 
where in an effort to study a polyoma virus antigen under the thymidine kinase 
promotor, these mice developed neuroblastoma-like tumours and preneoplastic 
lesions in the adrenal medulla (Aguzzi et al., 1990). This discovery was followed 
by others making transgenic mice with different constructs and seemingly by 
chance ending up with neuroblastoma-like tumours (Iwamoto et al., 1993; Pecori 
Giraldi et al., 1994; Servenius et al., 1994; Skalnik et al., 1991).  
However, Weiss and colleagues have genetically engineered a transgenic mouse 
that overexpresses the MYCN proto-oncogene under the control of the tyrosine 
kinase promoter, and these animals have a high prevalence of neuroblastoma 
(Weiss et al., 1997). 
The model showed that MYCN by itself could drive the tumourigenesis of 
neuroblastoma and that the gene dosage of MYCN was a direct contributor, as 
homozygous mice showed increased incidence and shorter latency of tumour 
formation (Weiss et al., 1997). Further, the model was shown to be metastatic and 
that the tumours displayed syntenic gains and losses of genetic material that can 
be observed in patients (Weiss et al., 1997). The transgenic mice were then 
shown to further have amplified the transgene in the tumours and, interestingly, no 
correlation between MYCN expression and transgene dosage or tumour latency 
was observed (Norris et al., 2000). It has also been shown that whilst normal litter 
mates develop hyperplasia in the ganglia that spontaneously regress this was 
delayed and incomplete in the transgenic mice, and the conclusion was put 
forward that the improper expression of MYCN drives tumourigenesis by disturbing 
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the normal process when these cells should be eradicated (Hansford et al., 2004). 
The histology of tumours from these animals (Moore et al., 2008) and 
characteristics of cell lines established from the tumours (Cheng et al., 2007) 
showed high similarity to human neuroblastoma.  
Several studies have further confirmed that genomic events in these mice are 
syntenic to those observed in patients (Hackett et al., 2003; Lastowska et al., 
2004; Weiss et al., 2000). There has been a number of treatment studies 
performed on these animals, including MYCN antisense oligonucleotide (Burkhart 
et al., 2003), anti-angiogenic TNP-470 (Chesler et al., 2007), methionine 
aminopeptidase inhibitor (Morowitz et al., 2005), retinoids (Liu et al., 2005), 
phosphatidyl-inositol 3 kinase (PI3K) inhibitor (Chesler et al., 2006), the histone 
deacetylase inhibitor Trichostatin A (Kuljaca et al., 2007; Liu et al., 2007), and 
cyclophosphamide (Chesler et al, 2008). Several genetic targets have been shown 
to be deregulated in the model, including the multidrug resistance-associated 
protein (MRP) where treatment sensitivity can be restored by the novel MRP1 
inhibitor Reversan (Burkhart et al., 2009). The ornithine decarboxylase 1 (ODC1) 
can be targeted using the suicide inhibitor DFMO (Hogarty et al., 2008; 
Rounbehler et al., 2009). Haploinsufficiency of the putative tumour suppressor 
Clustrin (Chayka et al., 2009) and transcription factor and potential oncogene 
HMGA1 (high mobility group A1 protein) (Giannini et al., 2005) has also been 
reported. Most recently, it has also been presented that expression of PHOX2B 
plays an important role in the pathogenesis of neuroblastoma in these mice (Alam 
et al., 2009).  
 
1.4. GALECTIN-1 
Galectins are a phylogenetically conserved family of lectins defined in 1994 as a 
shared consensus of amino-acid sequences of about 130 amino acids and the 
carbohydrate recognition domain (CRD) responsible for β-galactoside binding 
(Barondes et al., 1994).  
Galectin-1 (gal-1), the first protein to be discovered in the family is a 14 kDa lectin 
expressed ubiquitously in mammalian organism and has been reported to be 
expressed in many tumour types including astrocytoma, melanoma and prostate, 
thyroid, colon, bladder and ovary carcinomas (reviewed by Danguy et al., 2002). 
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Interestingly, in most cases such expression correlates with the aggressiveness of 
these tumours and the acquisition of metastatic phenotype. Many studies have 
demonstrated the involvement of gal-1 in various aspects of tumourigenesis and it 
has been described as a promising cancer target (see figure 1, reviewed in Liu & 
Rabinovich, 2005; Rabinovich, 2005; Salatino et al., 2008). 
Galectin-1 function has been found to be intricately linked to essential biological 
processes in tumour cells. It can act as an extracellular matrix protein to modulate 
cell adhesion (Hughes, 2001) as well as intracellularly by interaction with H-ras 
causing Ras membrane anchorage and cell transformation (Paz et al., 2001). 
Galectin-1 directs the transport of farnesylated H-ras to the Golgi apparatus in 
various systems (Belanis et al., 2008). Inhibition of H-ras/Galectin interaction by 
small molecule inhibitors, such as farnesylthiosalicylate, (Paz et al., 2001) has 
proved anticancer activity in various model systems and is now proceeding to 
clinical development. Additionally, galectin-1 knockdown has been shown to 
synergistically potentiate the actions of Temozolomide in a mouse metastatic 
melanoma model thus emphasising the role of galectin-1 in sensitizing tumour 
cells to chemotherapy (Mathieu et al., 2007). Galectin-1 also regulates complex 
signalling pathways involved in tumour–host interaction (Juszczynski et al., 2007; 
Rodig et al., 2008) and angiogenesis (Thijssen et al., 2006). By forcing activated T 
cells to undergo apoptosis (He & Baum, 2004), Gal-1 expression has been 
hypothesized to contribute to the tumour-immune escape. Inhibition of Gal-1 
function resulted in T-cell mediated tumour rejection (Rubinstein et al., 2004). Gal-
1 has been shown to contribute to tumour angiogenesis in a mouse melanoma 
model (Le Mercier et al., 2008a), and selective peptide inhibitors to Gal-1 have 
been developed that show profound antiangiogenic activity in vivo (Thijssen et al., 
2007). 
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Fig 1: Contribution of galectin-1 to tumour progression. Galectin-1 interacts with 
oncogenic HRAS and contributes to membrane anchorage of HRAS and tumour 
transformation. In addition, this protein modulates cell growth, cell adhesion and 
cell migration, thereby affecting the process of tumour metastasis. Furthermore, 
recent evidence indicates that tumour cells secrete substantial levels of galectin-1 
to evade T-cell-mediated responses. (from Rabinovich, 2005). 
 
Introduction 
22 
 
In gliomas, galectin-1 expression is elevated in patients with poor outcome, and 
moreover, galectin-1 expression was enhanced at the invasive front and 
stimulated glioma cell migration (Strik et al., 2007). In colon cancer, galectin-1 
expression was also positively correlated with disease progression. Galectin-1 is 
regulating inflammatory responses as well as the induction of T-cell apoptosis by 
interaction with CD3/CD7 (Toscano et al., 2007) and modulation of cell adhesion, 
at least in part, by the interaction with the beta-1 unit of integrin (reviewed by Liu 
and Rabinovich, 2005).  
Galectin-1 also emerged as an interesting target from both transcriptome and 
proteome studies of NB. Galectin-1 mRNA is up-regulated in patients with 
aggressive, relapsing NB (Schramm et al., 2005) and the protein was up-regulated 
in an in vitro model of aggressive, TrkB-expressing NB (Sitek et al., 2005). 
Previous work has identified gal-1 as important for migration and invasion of NB 
cells. In this study, the effects of blocking galectin-1 function on cell motility have 
been shown. Interfering with gal-1 functions reduced invasiveness and migration 
of human NB cells in vitro and these aggressive features were tightly linked to the 
expression and activation of the neurotrophin receptor, TrkB that is associated 
with poor prognosis in NB (Cimmino et al., 2009). Given the contribution of 
galectin-1 to tumour growth and metastasis, it is predicted that inhibitors of 
galectin-1 will find their way into cancer clinical trials, leading to delays in tumour 
progression and improvements in overall survival. 
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1.5. OBJECTIVES 
The aim of the present work is to evaluate galectin-1 as a drug target for the 
treatment of neuroblastoma. Previous work has identified gal-1 as important for 
migration and invasion of NB cells. Invasion and metastasis are among the most 
important problems to be addressed in NB therapy. While treatment of the primary 
tumour is feasible, dissemination of the disease is often fatal. However, the 
precise in vivo functions of galectin-1 are currently unclear. 
 
The specific goals of this work are: 
• Analyze the consequences of galectin-1 inhibition in NB 
experimental tumours 
• Study the effects of promising novel NB therapies after galectin-1 
knockdown i.e. HDAC inhibitors, temozolomide and 
farnesylthiosalicylic acid. 
• Establish an orthotopic metastatic model of neuroblastoma 
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2. MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. Chemicals and Consumables 
100 bp DNA Marker Invitrogen, Karlsruhe, Germany 
2-Mecaptoethanol Sigma, Diesenhofen, Germany 
Acetic acid Sigma, Diesenhofen, Germany 
Acetone Sigma, Diesenhofen, Germany 
Blasticidin Invitrogen, Karlsruhe, Germany 
Bromphenol blue Sigma, Diesenhofen, Germany 
BSA Sigma, Diesenhofen, Germany 
DMSO Merck, Darmstadt, Germany 
Dry milk powder Carl Roth, Karlsruhe, Germany 
Ethanol J.T. Baker, Deventer, Netherlands 
Ethidium Bromide Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Farnesylthiosalicylic Acid Cayman Chemicals, Ann Arbor, USA 
Glucose Carl Roth, Karlsruhe, Germany 
Glycerol Sigma, Diesenhofen, Germany 
Glycine Sigma, Diesenhofen, Germany 
Isopropanol Sigma, Diesenhofen, Germany 
Kanamycin Sulfate Invitrogen, Karlsruhe, Germany 
Whatman paper Biorad, München, Germany 
Methanol Sigma, Diesenhofen, Germany 
Novex® sharp Pre-stained Protein 
Marker 
Invitrogen, Karlsruhe, Germany  
NP-40 Sigma, Diesenhofen, Germany 
NUPAGE® 4-12% Bis-Tris Gels Invitrogen, Karlsruhe, Germany 
Paraformaldehyde Sigma, Steinheim, Germany 
PBS Gibco, Eggenstein, Germany 
Protein A/G PLUS-Agarose Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany 
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Proteinase Inhibitor Sigma, Diesenhofen, Germany 
siPORT™ NeoFX™ Transfection Agent Applied Biosystems/Ambion, 
Darmstadt, Germany 
Sodium Chloride Carl Roth, Karlsruhe, Germany 
Sodium Dodecylsulphate (SDS) GERBU Biotechnik GmbH, Gaiberg, 
Germany 
Sodium hydroxide Fluka Chemie GmbH, Buchs, 
Germany 
Suberoylanilide Hydroamic Acid (SAHA) Cayman Chemicals, Ann Arbor, USA 
Sucrose Sigma, Diesenhofen, Germany 
Temozolomide Tocris Bioscience, Ellisville, USA 
Tris Base Sigma, Diesenhofen, Germany 
Tris Hydrochloride Sigma, Diesenhofen, Germany 
Triton X-100 Sigma, Diesenhofen, Germany 
Trypton/Peptone Sigma, Diesenhofen, Germany 
Tween 20 Polysorbate Sigma, Diesenhofen, Germany 
Valproic Acid Sigma, Diesenhofen, Germany 
Yeast extract Roth, Karlsruhe, Germany 
Bradford Reagent Biorad, München, Germany 
Tryptone Carl Roth, Karlsruhe, Germany 
PeqGOLD Universal Agarose PeqLab; Erlangen, Germany 
Agar Carl Roth, Karlsruhe, Germany 
ISOTON® II Diluent Beckman Coulter GmbH, Krefeld, 
Germany 
Xylol Sigma, Diesenhofen, Germany 
Amersham Hybond™ ECL™  Amersham Biosciences Europe 
GmbH, Freiburg, Germany 
Fast Green FCF Sigma, Diesenhofen, Germany 
MOPS Carl Roth, Karlsruhe, Germany 
EDTA Feinbiochemica GmbH &Co, 
Heidelberg, Germany 
Tetracycline Invitrogen, Karlsruhe, Germany 
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BD Matrigel™ Basement Membrane 
Matrix. Cat No. 356231 
BD Biosciences, Bedford, MA, USA 
DAKO Pen DAKO Denmark A/S, Glostrup, 
Denmark 
Isofluran Delta Select GmbH, Dreieich, 
Germany 
Bepanthen Bayer Vital GmbH, Lerverkusen, 
Germany 
Betaisodona Mundipharma GmbH, Limburg, 
Germany 
0,9 % Saline Fresenius Kabi, Bad Homburg, 
Germany 
Xylazin 2% Ceva Tiergesundheit GmbH, 
Düsseldorf, Germany 
Ketamin 10% Ceva Tiergesundheit GmbH, 
Düsseldorf, Germany 
RIMADYL® Pfizer GmbH, Karlsruhe, Germany 
 
 
2.1.2. Buffers and reagents 
Fast Green Staining Solution 0,5% Fast Green FCF, 20%  Methanol, 
10% Glacial acetic acid  
PBST 0,02% Tween 20 in PBS 
BLOTTO 5% Fat dry milk powder in PBST buffer 
TAE buffer (50 x) 242 g Tris pH 8.5, 57.1 mL Glacial 
acetic acid, 100 mL 0.5 M EDTA in 1 
liter H2O 
4x NUPAGE LDS Loading buffer 424 mM TRIS-HCl, 564 mM TRIS Base, 
8% LDS, 2,04 mM EDTA, 40% Glycerin, 
0,88 mM Coomassie, 700 mM Phenol 
red 
Ripa Buffer 50 mM Tris-HCl pH 7,4; 150 mM NaCl, 
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1% NP-40; 1% Tween 20; 0,5% Doc 
(Dooxycholate), 0,1% SDS 
NP-40 Lysis Buffer 50 mM Tris-HCl pH 8,0; 150 mM NaCl, 
1% NP-40; 5mM EDTA 
20x MOPS-SDS Running Buffer 50 mM MOPS, 50 mM TRIS Base, 0.1% 
SDS, 1 mM EDTA 
 
2.1.3. List of primers and oligonucleotide sequences 
H1 Forward Sequencing Primer 5′-TGTTCTGGGAAATCACCATA-3′ 
M13 Reverse Primer 5′-CAGGAAACAGCTATGAC -3′ 
Galectin-1 shRNA sense 5´-CAC CGC GCC AGC AAC CTG AAT 
CTC AAC GAA TTG AGA TTC AGG TTG 
CTG GCG-3´ 
Galectin-1 shRNA reverse 5´-AAA ACG CCA GCA ACC TGA ATC 
TCA ATT CGT TGA GAT TCA GGT TGC 
TGG CGC-3´ 
Human Galectin-1 Forward 
Primer  
5´-CTCTCGGGTGGAGTCTTCTG-3´ 
Human Galectin-1 Reverse 
Primer 
5´-ACGAAGCTCTTAGCGTCAGG-3´ 
Mouse Galectin-1 Forward 
Primer 
5´-GTGTGCATCACCTTTGACCAGG-3´ 
Mouse Galectin-1 Reverse 
Primer 
5´-TGCCTTTATTGAGGGCTACAGG-3´ 
Human GAPDH Forward Primer 5´-CACCCATGGCAAATTCCATGGCA-3´ 
Human GAPDH Reversed Primer 5´-TCTAGACGGCAGGTCAGGTCCACC-
3´ 
Mouse GAPDH Forward Primer 5´-GTGAAGGTCGGTGTGAACG-3´ 
Mouse GAPDH Reversed Primer 5´-GGTGAAGACACCAGTAGACTC-3´ 
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2.1.4. Enzymes 
Enzymes Source 
GoTaq® DNA Polymerase Promega GmbH, Mannheim, Germany 
Taq-DNA Polymerase Invitrogen, Karlsruhe, Germany 
SuperScript® II Reverse Transcriptase Invitrogen, Karlsruhe, Germany 
RNaseOUT™ Recombinant 
Ribonuclease Inhibitor 
Invitrogen, Karlsruhe, Germany 
Ribonuclease H Invitrogen, Karlsruhe, Germany 
Random Primers Invitrogen, Karlsruhe, Germany 
My-Budget dNTP-mix Bio-Budget Technologies GmbH, 
Krefeld, Germany 
 
2.1.5. Commercial kits 
Kits Source 
BLOCK-iT™ Inducible H1 RNAi Entry Vector Kit Invitrogen, Karlsruhe, 
Germany 
RNeasy Micro Kit Qiagen, Hilden, Germany 
QIAGEN Plasmid Mini Kit  Qiagen, Hilden, Germany 
QIAfilter Plasmid Midi Kit Qiagen, Hilden, Germany 
peqGOLD Plasmid Miniprep Kit PEQLAB, Erlangen, Germany 
VECTASTAIN ABC Kit (Standard) Vector Laboratories, Inc, 
Burlingame, CA, USA 
ImmPACT™ DAB Vector Laboratories, Inc, 
Burlingame, CA, USA 
Amersham ECL Plus Western Blotting Detection 
Reagents 
Amersham Biosciences 
Europe GmbH, Freiburg, 
Germany 
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2.1.6. Antibodies 
Goat Anti-human Galectin-1 
 
1:200 in 
PBST 
R&D Systems, Wiesbaden-
Nordenstadt, Germany 
Rabbit Monoclonal Antibody 
against HRAS (Clone Y132) 
1:250 in 
PBST 
Origene, Rockville, MD, USA 
Rabbit polyclonal Ki-67 
Antibody 
1:250 in 
goat serum 
Abbiotec, San Diego, CA, USA 
Rabbit polyclonal CD31 (N-
term) Antibody 
1:300 in 
Goat serum 
Abbiotec, San Diego, CA, USA 
Mouse Monoclonal GAPDH 
Antibody, clone 6C5 
1:2000 in 
PBST 
Millipore GmbH, Schwalbach/Ts., 
Germany 
Rabbit anti-goat IgG-HRP: 
sc-2922 
1:10000 in 
PBST 
Santa Cruz Biotechnology Inc, 
Heidelberg, Germany 
Polyclonal Goat anti-mouse-
HRP. P0447 
1:5000 in 
PBST 
DAKO GmbH, Hamburg, 
Germany 
Goat anti-rabbit IgG-HRP sc-
2004 
1:1000 in 
PBST 
Santa Cruz Biotechnology Inc, 
Heidelberg, Germany 
Polyclonal Goat Anti-Rabbit 
Immunoglobulins/Biotinylated 
Code No. E 0432 
1: 1000 in 
goat serum 
DAKO GmbH, Hamburg, 
Germany 
 
2.1.7. Cell culture Materials 
DMEM Gibco, Eggenstein, Germany 
RPMI Medium Gibco, Eggenstein, Germany 
Fetal Bovine Serum (FBS) Gold PAA Laboratories GmbH, Cölbe, 
Germany 
Penicillin/Streptomycin Gibco, Eggenstein, Germany 
Opti®-MEM Gibco, Eggenstein, Germany 
Trypsine/EDTA Gibco, Eggenstein, Germany 
L-Glutamine Gibco, Eggenstein, Germany 
Zeocin™ Invitrogen, Karlsruhe, Germany 
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2.1.7.1. Medium for Bacteria Cell culture 
Medium Composition 
SOC 2% Tryptone, 0,5% Yeast extract, 10mM NaCl, 2,5mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose 
LB medium Per litre: 10 g tryptone, 5 g yeast extract, 5 g NaCl 
After autoclave sterilization, Ampicillin (kanamycin 50 µg/mL) 
was added to 100 µg/mL 
 
2.1.7.2. Bacteria strains and their characteristics 
Bacteria Strain Genotype of Bacteria Strain 
Echerichia coli DH5F´ DeoR, endA1,gyrA96, hsdR17(rkmk+), recA1, relA1, 
supE44, thi-1, (lacZYA-argFV169), 80lacZM15 
Top 10 Escherichia coli F´mcrA(mrr-hsdRMS-mcrBC); 80lacZM15; 
∆lacX74; recA1: deoR; araD139; ∆(ara-leu)7697; 
galU; galK; rpsL; (StrR); endA1; nupG 
 
2.1.7.3. Neuroblastoma cell lines and their origins 
Kelly DSMZ GmbH, Braunschweig, Germany 
SK-N-BE(2) DSMZ GmbH, Braunschweig, Germany 
SY5Y_TetR DSMZ GmbH, Braunschweig, Germany 
NXS2 DSMZ GmbH, Braunschweig, Germany 
 
2.1.8. Equipment  
Beckman Epics XL FACS Beckman Coulter, Fullerton, USA 
Coulter Counter Beckman Coulter, Fullerton, USA 
XCell SureLock™ Mini-Cell Invitrogen, Karlsruhe, Germany 
ELISA Reader KC Junior Biotek, Bad Friedrichshall, Germany 
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Rotixa 50S Hettich, Mülheim a.d.Ruhr, Germany 
Thermoblock Biometra, Göttingen, Germany 
BioDocAnalyze live Biometra, Göttingen, Germany 
UVIchemi Biometra, Göttingen, Germany 
C1000Tm Thermal Cycler Biorad, München, Germany 
NanoDrop™ ND-1000 
Spectrophotometer 
PEQLAB, Erlangen, Germany 
Ultracentrifuge Biofuge Fresco Kendro Laboratory products, Hanau, 
Germany 
Mini Centrifuge Roth GmbH, Karslruhe, Germany 
Vacuum Centrifuge SPD 1010 
Speedvac 
Thermo Savant, Hick, Germany 
MicroPorator-mini (MP-100) NanoEnTek Inc. Seoul, Korea 
Xcelligence Roche, Mannheim, Germany 
 
2.1.9. Surgical Equipment 
HAMILTON microlitre syringe (1701RN) 
and Needles 
Hamilton Bonaduz AG, Bonaduz, 
Switzerland 
Splinter Forceps; BD311R, BD312R  Aesculap AG, Tuttlingen, Germany 
Iris Dissecting Forceps; OC 025,  Aesculap AG, Tuttlingen, Germany 
Dissecting and Ligature Forceps; 
BJO73R 
Aesculap AG, Tuttlingen, Germany 
Dissecting Scissors Aesculap AG, Tuttlingen, Germany 
Surgical Scissors Aesculap AG, Tuttlingen, Germany 
Coated VICRYL® (polyglactin 910) 
Suture 
Johnson & Johnson, Neuss, 
Germany 
Shaving Machine Wella AG, Darmstadt, Germany 
Disposable Scalpel (15) Servoprax® GmbH, Wesel, 
Germany 
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2.2. Methods 
2.2.1. Cell Culture 
NB Cell lines were cultured at 37°C, 5% CO2. Kelly and SK-N-BE(2) were 
maintained in RPMI 1640 medium with 10% FCS and Pennicillin/Streptomycin 
(Pen/Strep). NXS2 was cultured in DMEM medium with 10% FCS and Pen/Strep. 
Stable SH-SY5Y cell lines which express the TetR gene (SH-SY5Y_TetR) from 
the pcDNA™6/TR were maintained in RPMI 1640 medium (10% FCS and 
Pen/Strep) and 7,5 µg/mL Blasticidin. 
 
2.2.2. Drug Formulations and Administration 
TMZ was dissolved in DMSO as a stock solution of 100 mM. The stock solution 
was diluted with PBS to a final concentration of 5 mg/kg prior to use in vivo. SAHA 
was dissolved in DMSO to a stock concentration of 2 mM.  
FTS stock solution of 100 mM in chloroform was prepared aliquoted and stored at 
-80°C. Prior to use in vitro, the chloroform was evaporated, DMSO (40 µL) is 
added, the tube is vortexed and RPMI 1640/10% FCS (360 µL) is added. The final 
DMSO concentration was adjusted to 0.1% in all experiments. For in vivo 
experiments, the chloroform is evaporated from the FTS stock solution (84 µL 
aliquot), 8 µL ethanol is added. 7 µL of 1M NaOH is then added followed by 
addition of 1.48 mL PBS. This gives a final concentration of 2 mg FTS/mL. 
 
2.2.3. Proliferation/Cytotoxicity Assay 
Cell proliferation and cytoxicity after drug treatment and/or siRNA transfection was 
determined using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) which determines the mitochondrial activity in living cells and also by the 
xCELLigence system (Roche). 
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2.2.3.1. MTT Proliferation Assay 
5 x 103 cells (SK-N-BE(2) and NXS2) or 1.5 x 104 Kelly cells were plated in 96 
multiwell plates. Cells were treated/transfected as described at the indicated times 
and the MTT was performed 72 hours later. The cells were incubated with 1.25 
mg/mL MTT for 4 hours at 37°C and then the formazan salts formed was lysed 
with MTT lysis reagent (10% SDS, 5% glacial acetic acid in DMSO) for one hour. 
Results were quantified by measuring the absorbance at 570 nm. The 
concentration of drug required for 50% reduction of cell proliferation (IC50) was 
extrapolated from dose-response curves. Each value represents six replicates, 
and each experiment was repeated at least three times. 
 
2.2.3.2. xCELLigence Cellular Analysis 
The xCELLigence system monitors in real time the electrical impedance across 
interdigitated micro-electrodes integrated on the bottom of tissue culture plates 
(termed “E-Plates”) as a quantitative measure of the biological status of cells. This 
is recorded as a dimensionless parameter termed Cell Index (CI) which is a 
measure of the cell number, viability, and morphology. The CI of a given well will 
be zero if there are no cells present and this will increase as more cells attach to 
the bottom of the plates (electrodes). Any change in the cell morphology, adhesion 
or viability degree will change the CI. The major advantage of this system over the 
MTT is that it provides the dynamic monitoring of changes in cell status as 
opposed to a given end point. 
5 x 103 SK-N-BE(2) cells were transfected in the 96-well E-plates. After 24 hours 
the medium was replaced with medium containing the indicated drugs and the cell 
status was monitored for another 72 hours. The experiment was performed in 
triplicate for each value and repeated at least twice. 
 
2.2.4. shRNA Regulated Galectin-1 Expression 
Plasmids expressing shRNA targeting galectin-1 was constructed using the  
BLOCK-iT™ Inducible H1 RNAi Entry Vector Kit according to the manufacturer’s 
manual. In summary, oligonucleotides encoding the sense and antisense strands 
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of shRNA against galectin-1 (see section 2.1.2) were annealed and cloned into the 
pENTR™/H1/TO vector to transform TOP10 E. coli. Ten entry colonies were 
cultured in LB medium containing 50 µg/mL kanamycin. The plasmids DNA were 
isolated using the peqGOLD Plasmid Miniprep Kit (PeQLab) following the 
manufacturer´s protocol. The constructs were then sequenced to confirm the 
presence and correct orientation of double stranded oligonucleotide insert. 
Glycerol stocks of positives clones were stored at -80°C for further use. 
In order to generate stable cell lines that constitutively express the plasmid 
construct, SH-SY5Y_TetR cells were transfected with 4 µg plasmid DNA using the 
microporator according to the manufacturer’s protocol. A plasmid expressing GFP 
was used to control transfection efficiency. The cells were maintained in 7.5 µg/mL 
Blasticidn and 50 µg/mL Zeocin to maintain selection pressure. 
 
2.2.5. siRNA Transfection 
Cell lines were transiently transfected with siRNAs directed against Gal-1 using 
siPORT™ NeoFX™ Transfection Agent according to instructions provided by the 
manufacturer (Ambion, Darmstadt, Germany). An alexaFlour-labeled scrambled 
siRNA (Qiagen) was used to control for transfection efficiency and as a control for 
Gal-1 mediated effects. Untreated cells and cells transfected with siPORT NeoFX 
buffer only were included as negative controls. 
5 x 103 SK-N-BE(2) and NXS2 cells per well or 1.5 x 105 cells per well were 
transfected in 96-well and six-well plates respectively. The final siRNA 
concentration in all experiments was 30 nM. The galectin-1 expression level was 
evaluated after five days. 
Cells (1.5 x 106 cells/75 cm flask) for mouse tumour grafting were transfected on 
day one. The cells were trypsinised and re-transfected 72 hours (day 4) after the 
first transfection. The knockdown efficiency was monitored by western analysis 
after another 72 hours (day 8), which is the time point of mice tumour grafting. 
 
2.2.6. Reversed Transcriptase PCR Analysis 
Total RNA from NB cell lines transfected with siRNA and/or treated with drugs was 
prepared using Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany) and 
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subsequently transcribed into cDNA using SuperScript® II Reverse Transcriptase 
and RNaseOut (Invitrogen). Relative quantification of Gal-1 mRNA expression was 
achieved both using Taqman Assay Hs00355202_m1 (Applied Biosystems, Foster 
City, CA, USA) and the standard curve based method. For the semi quantitative 
RT-PCR analysis, the cDNA was amplified and subjected to electrophoretic 
separation on a 2% agarose gel containing 0.5 mg/mL ethidium bromide. The PCR 
products were detected using UV transillumination, photographed and the rations 
of galectin-1 to GAPDH were densitometrically determined using the 
BioDocAnalyze live software (Biorad). All assays were carried out in triplicate. 
Galectin-1 mRNA expression was normalized to the averaged GAPDH expression 
in each sample. Data are presented as mean values ± SD. 
 
2.2.7. Co-Immunoprecipitation 
Cells were washed with cold PBS and lysed using the NP-40 lysis buffer 
supplemented with Protease inhibitor (Roche). Approximately 3 mg whole cell 
lysate (evaluated by Bradford assay) were adjusted to 500 µL and precleared with 
protein A/G PLUS-Agarose before being immunoprecipitated overnight with 2,5 µg 
of antibody and 50 µL protein A/G PLUS-Agarose. The precipitates were washed 
with lysis buffer, eluted with SDS sample buffer and then subjected to SDS-PAGE 
and western immunoblotting as described below. 
 
2.2.8. Western Analysis 
Cell lines were plated or transfected as described above (1.5 x 105 cells/well) in six 
welled plates one day before treatment with indicated drugs. After 72 hours of 
treatment with drugs at indicated concentrations or with control vehicle, the cells 
were washed in cold PBS and lysed using the Ripa lysis buffer containing 
protease inhibitor followed by high speed centrifugation. Cell lysates (10 – 20 µg) 
were separated on NuPAGE BisTRIS Gel (4-12% Polyacrylamide-Gradient) and 
blotted onto nitrocellulose membranes. Membranes were blocked for one hour in 
BLOTTO (5% skimmed milk in PBS supplemented with 0.02% Tween-20). 
Membranes were incubated overnight with primary antibody at 4°C. After washing 
three times with PBST (PBS with 0.02% Tween-20), the blots were incubated for 
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one hour with horseradish peroxidase-conjugated secondary antibody at room 
temperature. Detection of the bands was done with enhanced chemiluminescence 
ECL plus kit (Amersham). 
 
2.2.9. Cell Cycle Analysis 
Parallel experiments were performed as described for western analysis for the 
assessment of cell cycle distribution by fluorescence-activated cell sorting (FACS) 
analysis at 24, 48 and 72 hours after treatment with drugs. Cells were harvested, 
centrifuged, washed with cold PBS and then fixed in ice-cold 70% ethanol at 4°C 
overnight.  After centrifugation at 1200 rpm for 5 minutes at 4°C, cells were re-
suspended in PBS supplemented with 0.2-0.5 mg/mL RNase and then incubated 
for one hour at 37°C. The cells were stained with 10 µg/mL Propidium Iodide and 
the cell cycle phase distributions were analysed with a FACS flow cytometer 
(Bechman-Coulter Epics XL). 
2.3. Animal Experiments 
2.3.1. Ethics and Animal Care 
All the in vivo experiments described in this study were performed with locally bred 
A/J and nu/nu mice on the basis of authorisation number 9.93.2.10.34.07.313 of 
the Animal Ethics Committee. The mice were used according to institutional 
guidelines when they were 7-10 weeks old. 
2.3.2. Microsurgical Procedures 
A/J mice were anaesthetised using 0.1 mL/10g of the anaesthesia formulation ( 5 
mL 0.9% NaCl, 1 mL 10% Ketamine, 0.25 mL Xylazine) intraperitoneally (ip). Fur 
on the left side of the body between the fore and the hind legs was shaved and 
prepped with betaisadone. Bepanthen was applied to the eyes to maintain eye 
moisture and protection against irritants. An incision was made over the left retro-
peritoneal space to expose the adrenal gland and a total of 6 x 105 NXS2 cells in 
10 µL PBS was injected into the left adrenal gland with a disposable needle 
(Hamilton) on a 10µL Hamilton syringe. The incision was sutured with a 5.0 Vicryl® 
(Johnson and Johnson). Each animal was subcutaneously administered 0.02-0.04 
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mL of Temgesic. The mice were kept warm during anaesthesia, surgery and 
recovery on a thermal plate at 37°C and if necessary, anaesthesia was maintained 
using intranasal administration of Isoflurane. During the first week after surgery or 
as long as was dimmed necessary, the animals were supplied with 4 mg/kg 
Rimadyl® diluted in 0.9% NaCl to alleviate the pains. The health of the mice was 
closely monitored every day for the first two weeks and three times a week 
thereafter until mice were sacrificed. 
2.3.3. Mouse Grafting and Treatment Schedules 
A/J mice were shaved and the skin decontaminated with betaisadone at the site of 
injection and 2 x105 NXS2 cells in 200 µL Matrigel were injected s.c. into the right 
flank of each recipient mouse. In other experiments, galectin-1 siRNA transfected 
cells [2 x 105 Kelly or 1.0 x107 SK-N-BE(2)] in 200 µL matrigel were injected s.c. 
into the right flank of nude mice. The mice were randomly assigned into one of the 
experimental groups with six mice in each group. The indicated treatment 
schedules were initiated one after mouse tumour grafting. The experimental 
protocols are detailed in the legends of the results section. The tumours were 
measured everyday for the synografts and three times a week for the xenografts 
using a digital calliper. Tumour volume was calculated by using the formula: Vtumour 
= Length x width x height. Animals were sacrificed when the tumour volume 
reached or exceeded 1 cm3.                                                                              
2.3.4. Histology 
Mice were killed by cervical dislocation and the tumours were excised. The lungs, 
kidney and liver of mice that were orthotopically grafted were also removed for 
assessment of tumour metastasis. These samples were fixed in 4% 
paraformaldehyde and then embedded in paraffin wax   for conventional 
hematoxylin-eosin staining or immunohistochemical analysis.  
2.3.5. Immunohistochemistry 
Four-micrometer sections were deparaffinised and hydrated by xylene. The slides 
were then incubated for 30 minutes in 3% H2O2 in methanol to quench the activity 
of any endogenous peroxidase. After washing, the slides were blocked in 10% 
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goat serum in PBS for one hour at RT followed by overnight incubation at 4°C with 
Ki67 antibody. The slides were then washed thrice with PBS and incubated with 
secondary antibody for 1 h at RT. Subsequently the sections were rinsed and the 
antigen-antibody binding was visualised by means of the avidin-biotin complex 
(ABC) method using DAB (3,3’-diaminobenzidine) as chromogen. 
Immunoreactions were visualized with the ABC complex diluted 1:50 in 
phosphate-buffered saline (Vectastain, Vector, Burlingame, CA, USA). The 
number of positive cells was scored and graphed by averaging three repeated 
assessments. 
 
2.3.6. Statistical Analysis 
Results are expressed as mean values with standard deviations (SD). A two-tailed 
unpaired t-test was used to analyse the statistical difference between treatment 
groups in all in vitro assays. Survival analyses were carried out by means of 
Kaplan–Meier curves and the log-rank test. All statistical tests were carried out 
using GraphPad Prism™ software (GraphPad™, San Diego, Calif., USA). P < 0.05 
was considered as a statistically significant result. 
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3. RESULTS 
3.1. Transient siRNA/shRNA Directed Galectin-1 Downregulation 
The necessity of a gene or protein for a particular biological function is often 
investigated by loss-of-function studies. RNAi has the potential to mediate the 
long- or short-term silencing of gene expression at the DNA, RNA and/or protein 
level (Martin & Caplen, 2007). The expression level of galectin-1 was analysed in 
a panel of NB cell lines (Fig 2). Galectin-1 is abundantly expressed in all cell lines 
analysed except in Kelly cells which show very minimal amount of galectin-1 
protein expression. 
 
Fig 2: Expression of Galectin-1 in Neuroblastoma cell lines: 40 µg of protein 
extract of each cell was loaded per lane and the blot was probed with 
galectin-1 antibody. The blot was stripped and re-probed with antibody 
against GAPDH as loading control. 
Galectin-1 shRNA was used in order to stably and specifically knockdown galectin-
1 in SH-SY5Y that stably expresses the Tet repressor to enable conditional 
tetracycline-regulated galectin-1 expression. Transient induction shows ~35% of 
galectin-1 reduction compared to non-induced transfectants (Fig 3). Generation of 
stable transfected clones was not possible because the cells ceased growing or 
died after about six weeks in selection medium. Complete removal of the selection 
pressure did not change cell growth characteristics. 
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In other experiments, a specific anti-galectin-1 siRNA maximally reduced the 
galectin-1 mRNA level in the cell lines, Kelly, SK-N-BE(2) and NXS2 4 days post 
transfection in comparison to untreated cells (Fig 4). Galectin-1 protein expression 
was greatly reduced in NXS2 cells while there seem to be virtually no decrease in 
galectin-1 protein levels in SK-N-B(2) (Fig 5A). However, re-transfection of the 
cells showed an overwhelming decrease in galectin-1 protein in both SK-N-BE(2) 
and NXS2 cells 8 days (day of mice tumour grafting) after the first transfection (Fig 
5B).  
Fig 3: Inducible galectin-1 shRNA mediated transient knockdown of galectin-1. SH-
SY5Y-TetR cells were transfected with pENTR™H1/TO entry constructs containing 
shRNA targeting galectin-1 or with a GFP-expressing plasmid vector and grown in 
medium containing zeocin and blasticidin for selection of transfectants. 
Untransfected and cells transfected with transfection reagent alone (blank control) 
were used as controls. 24 hours after transfection, the medium was replaced with 
medium containing 1 µg/mL tetracycline. Total RNA was extracted after 72 hours 
induction with subsequent cDNA synthesis. Galectin-1 mRNA was quantified using 
real time RT-PCR normalised to GAPDH as house-keeping gene.  
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Fig 4: Galectin-1 siRNA knockdown of galectin-1 mRNA expression: NB cell lines 
were transfected with galectin-1(Gal-1) or scrambled (scr) siRNA in 96 well plates. 
After 24 hours, the medium was changed and cells were grown for another 72 
hours upon which total RNA was extracted. cDNA was synthesized and used for 
real time RT-PCR analysis of gal-1 mRNA expression normalized to GAPDH.  
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3.2. HDAC Inhibitors inhibit proliferation of NB cells in vitro 
Previous studies have shown that HDAC inhibitors inhibit NB cell proliferation and 
apoptotic cell death (Deubzer et al., 2007; Michealis et al., 2004). The ability of 
HDAC inhibitors VPA and SAHA to inhibit NB cell proliferation was assessed using 
the MTT assay. NB cell lines were treated with varying concentrations of VPA (0, 
0.4, 0.8, 1.2, 1.6, 2.0 mM) or SAHA (0.1, 0.25, 0.5, 0.75, 1.0 µM) for 72 hours and 
dose-response curves were plotted with compound concentration against 
percentage of viable cells (Fig 6A and B). Compounds showed antiproliferative 
activity in a dose dependent manner with VPA and SAHA IC50 values at 1.1, 1.19, 
1.2 mM and 0.57, 0.8, 0.85 µM for Kelly, SK-N-BE(2) and NXS2 cells respectively.  
 
Fig 5: Western blot analysis depicting the expression levels of galectin-1 
protein after gal-1 siRNA transfection. Cells were transfected with gal-1 
or scr siRNA or left untransfected (NT). Protein extracts were collected 
on day 4 (A) or the cells were trypsinised, re-transfected and grown for 
another 72 hours (day 8) before protein extraction (B). 10 µg of protein 
was loaded per lane and GAPDH blots were used to assess equal 
loading in each experiment. 
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Fig 6: Effect of HDAC inhibitors on proliferation of NB cell lines. The cells were 
treated with the indicated doses of VPA (A) and SAHA (B) for 72 hours.   
Effect on proliferation was assayed by MTT as described in materials and 
methods. Untreated cells served as controls and were set to 100%. 
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Fig 7: HDACi upregulate the expression of galectin-1 in NB cells. Cells 
were treated with 0.1% DMSO or the IC50 concentrations of HDACi as 
indicated or left untreated (NT) for 72 hours. cDNA was synthesised from 
extracted RNA and galectin-1 mRNA level was measured by semi-
quantitative RT-PCR. Data represent mean ± SD of three independent 
expriments A = NXS2: B = SK-N-BE(2): C = Kelly. 
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Next, experiments were performed to examine if the treatment of NB cells with 
HDACi alters the expression of galectin-1. Contrary to our belief that HDACi 
downregulate galectin-1 expression, the results show that HDACi actually increase 
the expression of galectin-1 in NB cells (Fig 7). VPA appears to be a more potent 
regulator of galectin-1 expression than SAHA since it shows a higher up-regulation 
of galectin-1. 
3.3. Effect of FTS and TMZ on Neuroblastoma Growth in vitro 
In similar experiments to those previously described above single agent TMZ (0, 
40, 80, 120, 160, 200 µM) had weak effect on the proliferation of all NB cell lines 
tested with a growth inhibition of ~68 - 85% at a concentration of 200 µM (Fig 8). 
On the other hand Kelly and SK-N-BE(2) were resistant to FTS treatment (0, 20, 
40, 60, 80, 100 µM) with an IC50 > 100 µM whereas NXS2 was more sensitive to 
FTS with an IC50 of 49 µM. 
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3.4. Effects of Combining TMZ to FTS in NB Cells in vitro 
The combination of drugs in various human cancer regimens is usually more 
effective than mono-drug therapy. Also it has been reported that FTS sensitizes 
human melanoma to the effects of Dacarbazine which is an Imidazotetrazine 
compound like TMZ in vivo (Halaschek-Wiener et al., 2003). The potential 
synergistic or additive potential of FTS to TMZ was evaluated. To pursue this goal, 
NB cells were treated with a clinically achievable dose (100 µM) of TMZ (kanzawa 
et al., 2004) alone and in combination to a single concentration of FTS. The 
concentration that approximates to the IC50 (50 µM) as determined by MTT was 
used for NXS2. The concentration of 75 µM was chosen for use in SK-N-BE(2) 
and Kelly cells because it is the concentration that has been mostly used in most 
publications (Kloog et al., 2005). Combining FTS to TMZ resulted in a statistically 
significant additive growth-inhibitory effects in both human cell lines tested when 
Fig 8: Proliferative response of NB cell lines to single agent TMZ or FTS. Cell 
lines were seeded in 96 well plates and treated with indicated concentrations of 
drugs or untreated (control) 24 h later for 72 h. The proliferation was evaluated 
using the MTT assay. 
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compared with control (SK-N-BE(2), 72.18±2.64 % of control, P = 0.0069 and 
Kelly, 65.1±1.36 % of control, P= 0.0064) but not in NXS2 cells (Fig 9). However 
only SK-N-BE(2) resulted in a statistically significant reduction in cell survival when 
compared to single agent FTS with P = 0.0298 but not with TMZ, P= 0.0927. The 
difference in combination therapy to mono-therapy did not reach statistical 
significance in both NXS2 and Kelly cells.  
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Fig 9: Anti-proliferative effect of combination of TMZ and FTS in NB cells. Cell 
lines were seeded in 96 well plates and treated with FTS alone 50 µM for 
NXS2 cells or 75 µM for SK-N-BE(2) and Kelly cells, or in combination with 
100 µM TMZ or left untreated (NT = control) 24 h later for 72 h. The 
proliferation was evaluated using the MTT assay. Indicated P values 
compared with blank control (DM = 0.1 % DMSO). A. NXS2. P = 0.0534, 
single agent TMZ versus combination group. B, SK-N-BE(2). P = 0.0927, 
combination group versus TMZ. C. Kelly. P = 0.2877, combination group 
versus TMZ. 
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Next the expression of galectin-1 after treatment with TMZ or FTS or drug 
combination was evaluated in parallel experiments to those performed above to 
explore the mechanisms of the various drugs cytotoxicity in relation to galectin-1 
expression.  
 
 
 
 
  
Fig 10: Effect of TMZ and FTS on galectin-1 expression in NB cells 
determined by semi quantitative RT-PCR. A, NXS2 and B, SK-N-
BE(2) cells 
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Furthermore the effect of TMZ and FTS to changes in cell cycle distribution was 
appraised by flow cytometry. TMZ is known to induce G2/M cell cycle arrest in 
various brain tumours. As shown in Fig 11 TMZ caused a minimal increase (~ 10 
%) in population at the G2/M Phase and a decrease in the population at the G1 in 
all NB cell lines though this changes was not statistically significant (P > 0.05, TMZ 
Vs DMSO control). FTS however did not show any changes in cell cycle 
distribution of cells or apoptosis as depicted in the cell population at the sub G1 
Phase in all cell lines. This result is surprising in the case of NXS2 where FTS 
shows strong growth-inhibitory effects as depicted by proliferation assay. This 
might suggest that decrease in cell viability by FTS in NXS2 might not be 
attributed to changes in cell cycle. Combination of TMZ and FTS did not alter 
these results in all cell lines tested. 
 
 A 
Results 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 11: Flow cytometric analysis of cell cycle distribution after treatment with 
TMZ and FTS. Cells were seeded for 24 h in 6 well plates and treated for 72 
hours with 100µM TMZ alone, 50 µM FTS alone ( A = NXS2) or 75 µM FTS ( 
B = SK-N-BE(2) and C = Kelly), or in combination. Data shown are 
representative of three independent experiments. 
C 
B 
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Parallel experiments were also performed for the analysis of galectin-1 expression 
after treatment with compounds in order to assess cell cycle changes in relation to 
galectin-1 expression (Fig 12).  
 
 
 
 
 
 
 
 
 
 
FTS and TMZ cause only slight changes in the expression of galectin-1 protein 
level in SK-N-BE(2) and NXS2 cells. This indicates that the TMZ-induced higher 
expression of galectin-1 in NXS2 cells at the mRNA level is not observed at the 
protein level.  
3.5. Galectin-1 co-localises with HRAS in Neuroblastoma 
Previous reports have demonstrated the association of galectin-1 to HRAS in 
transformed endothelial cells and the potential of FTS to disrupt this association 
(Rotblat et al., 2004). To further explore the mechanism of action of FTS in NB 
cells, the interaction of Galectin-1 and HRAS was examined by co-
immunoprecipitation. HRAS was immunoprecipitated (IP) using anti-HRAS 
antibody and then blotted with anti-galectin-1 antibody. The results show that 
HRAS co-immunoprecipitates with galectin-1 in both NXS2 and SK-N-BE(2) (Fig 
13) suggesting that the effect of FTS in NB cells is not dependent on the galectin-
1/HRAS interaction. 
 
Fig 12: Impact of TMZ and FTS treatment to galectin-1 expression in NXS2 and SK-
N-BE(2) cells as judged by Western Blot analyses. A= untreated cells, b = 0.1 % 
DMSO, c and d = 25 and 50 µM or 50 and 75 µM FTS for NXS2 and SK-N-BE(2) 
respectively, e = 100 µM TMZ, f = combination treatment. 
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3.6. Galectin-1 silencing in Neuroblastoma does not potentiate the anti-
proliferative activity of HDAC Inhibitors, FTS or TMZ in vitro 
Galectin-1 knockdown has previously been shown to increase the anti-tumour 
effects of cytotoxic, pro-autophagic and pro-apoptotic drugs both in vitro and in 
vivo (Le Mercier et al., 2008b). We have also recently demonstrated the effects of 
galectin-1 on NB cells migration (Cimmino et al., 2009) which in turn has been 
shown to sensitise cells to cytotoxic drugs, hence the power of galectin-1 silencing 
to sensitise NB cells to the anti-tumour effects of HDACi, FTS and TMZ was 
examined in vitro.
Fig 13: Galectin-1 co-immunoprecipitates with HRAS in NB cells. Protein 
extracts were immunoprecipitated with HRAS monoclonal antibody and the 
blotted with galectin-1 antibody. Cell lysate from whole protein extracts was used 
as positive control and the eluant after IP (IPctrl) was used as negative control. 
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Fig 14: Effect of galectin-1 knockdown and treatment with VPA. NB cells were 
transfected with siRNA against galectin-1 (gal-1 si) or scrambled siRNA (scr si) 
and/or treated with the IC50 concentration of VPA for 72h. Statistical analysis 
was performed by t-test of six independent experiments. Untransfected and 
DMSO vehicle treated cells were included as controls. Anti-gal-1 plus VPA was 
tested against scr si plus VPA. There is a significant decrease in proliferation 
using the combinatory treatment when compared to VPA as a single agent only 
for SK-N-BE(2) cells (P = 0.0029). This is not the case with NXS2 cells, P = 
0.1742 and Kelly cells, P= 0.3591).  
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Galectin-1 knockdown did significantly inhibit cell proliferation in SK-N-BE(2) ( P = 
0.0294) but not in NXS2 (P = 0.0611) and Kelly (P = 0.1051) cells when compared 
with scrambled siRNA treated (control) group. Decreasing galectin-1 in SK-N-
BE(2) cells resulted in a greater VPA-induced anti-proliferative effects (P= 0.0029) 
in comparison to cells treated with scrambled siRNA and VPA (Fig 14). However, 
there were no significant differences in proliferation in NXS2 and Kelly cells 
between the two groups. 
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On the other hand galectin-1 silencing did not cause a marked difference in the 
proliferation of NB cells to the effects of SAHA (Fig 15) in comparison with mock 
transfected cells treated with SAHA. However, there was a significant sensitivity of 
galectin-1 knockdown to effects of SAHA in NXS2 cells (P = 0.0012). 
Furthermore, silencing galectin-1 greatly reduced the percentage of viable cells 
when treated to TMZ than treatment with TMZ alone in all NB cells tested with 
NXS2 displaying the most pronounced effect.. Also, decreasing endogenous 
expression of galectin-1 weakly lowered the viability of NB cells when treated with 
TMZ (NXS2, P = 0.0227; SK-N-BE(2), P =  0.0878) when compared to cells 
treated with scrambled siRNA plus TMZ. 
Fig 15: Proliferative effects of galectin-1 knockdown and treatment with 
SAHA. Representative data of 6 independent experiments are shown. Gal-1 
knockdown + SAHA versus scr si + SAHA (NXS2, P = 0.0660; SK-N-BE(2), P 
= 0.1903). Gal-1 + SAHA versus single agent SAHA (NXS2, P = 0.0012; SK-
N-BE(2), P = 0.2562; Kelly, P = 0.2246). 
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The effects of combining the knockdown of endogenous galectin-1 and FTS was 
tested in SK-N-BE(2) cells and NXS2 cells. FTS did not significantly reduce cell 
viability after galectin-1 knockdown in NXS2. Galectin-1 silencing appeared to 
sensitise SK-N-BE(2) cells to FTS (P = 0.0340) however when compared with 
scrambled siRNA and FTS treated cells, the effect was modest and not statistically 
significant (P = 0.0820). Results representative of six independent experiments are 
shown in Fig 16 below. These results therefore demonstrate that TMZ has very 
minimal potential in synergy to galectin-1 silencing in NB cells in vitro. 
Fig 16: Effects of galectin-1 knockdown and treatment with 100 µM TMZ. 
Galectin-1 downregulation reduces cell proliferation in NB cells. NXS2, P = 
0.0227; SK-N-BE(2), P = 0.0878 ( TMZ alone Vs si gal-1+TMZ). Comparing 
siRNA gal-1 plus TMZ knockdown versus TMZ alone; NXS2, P = 0.0003; 
SK-N-BE(2), 0.0131; Kelly, P = 0.0084. 
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Fig 17: Effects of galectin-1 knockdown and combination with FTS. The 
concentration used in NXS2 cells was 50 µM and 75 µM for SK-N-BE(2). FTS 
does not show a synergistic effect to cell proliferation in NXS2 cells. Anti-gal-
1 plus FTS versus scr si plus FTS; NXS2 P = 0.1182; SK-N-BE(2), P = 
0.0820. FTS alone compared to FTS plus siRNA gal-1 knockdown; NXS2, P 
= 0.77364; SK-N-BE(2), P = 0.0340). 
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Based on the results obtained by MTT assay, the power of downregulating 
galectin-1 in potentiating the anti-tumour effects of HDACi, TMZ and FTS was also 
assessed using the XCelligence device (Roche), which has the advantage of real 
time cell analysis compared to conventional end-point analyses. For this purpose 
SK-N-BE(2) cells were used in parallel experiments to those described above (Fig 
14- 17). The results confirm that knocking down galectin-1 significantly inhibit cell 
proliferation in SK-N-BE(2) cells as shown in Fig 18 below. This is in contrast to 
results obtained in melanoma cells where galectin-1 knockdown does not alter cell 
proliferation in vitro (Mathieu et al., 2007). Again, the results are in agreement that 
TMZ and FTS at the concentrations used do not inhibit cell growth and also that 
they do not result in any additive growth-inhibitory effects of galectin-1 silencing 
(Fig 18 C and D). However XCelligence analysis reveals that there is a strong 
synergistic effect of galectin-1 downregulation to the cytotoxic effects of SAHA (Fig 
18 B) contrary to results obtained by MTT assay. A possible explanation to this 
might be that SAHA induces a more potent effect on cell attachment/motility than 
VPA, an aspect which cannot be reflected by MTT assay. Furthermore, galectin-1 
silencing does not sensitise SK-N-BE(2) cells to the cytotoxic effects of VPA as 
depicted previously (Fig 18 A). 
 
 
 
 
A 
Results 
61 
 
B 
C 
Results 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
Fig 18: Real time measurement of cell proliferation in vitro using the XCelligence 
(Roche) device. The cell index is proportional to the impedance due to cell 
adhesion and is equivalent to cell viability. Galectin-1 siRNA (blue lines) 
significantly reduced cell proliferation of SK-N-BE(2) cells. “Controls” used 
include cells treated with 0.1 % DMSO vehicle control (brick red lines) or cells 
transfected with scrambled siRNA (scr si) unrelated to any gene (green lines). A, 
Treatment of cells with gal-1 siRNA and 1.2 mM (IC50) VPA (sky blue lines) did 
not show any significant reduction in cell viability to cells treated with VPA and 
scr si whereas B; Significant decrease in cell viability of cells treated with 0.80 
µM SAHA (IC50) and gal-1 siRNA (yellow lines) compared to scr si plus SAHA 
treated cells (yellow lines). C: Treatment of cells with 100 µM TMZ (light red 
lines) results in no significant decrease in cell proliferation in and also did not 
result in any significant additive anti-proliferative effect to the gal-1 siRNA (light 
blue lines) when compared to treatment controls (yellow lines). D; FTS at 75 µM 
(light red lines) virtually did not alter the cell viability of cells and also did not 
result in any synergy to the growth-inhibitory effects of gal-1 siRNA (blue and sky 
blue lines). 
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3.7. The anti-proliferative activity of galectin-1 downregulation is not 
accompanied by changes in cell cycle distribution. 
The effect of galectin-1 knockdown on changes in cell cycle was examined by flow 
cytometry. In addition, it was interesting to investigate the effects of galectin-1 
knockdown and TMZ treatment since this was chosen to be assessed in vivo. The 
effect of TMZ on the expression of galectin-1 protein after siRNA treatment was 
also examined by western blotting (Fig 19). Apparently, TMZ did not change 
galectin-1 expression after siRNA galectin-1 knockdown.  Anti-galectin-1 siRNA 
did not alter the cell cycle distribution of both NXS2 and SK-N-BE(2) cells (Fig 20) 
when compared to cells treated with scrambled siRNA. This results show that the 
anti-proliferative effect of galectin-1 knockdown is not related to any changes in 
cell cycle. Furthermore, galectin-1 silencing did not cause or enhance the TMZ-
induced increase of cells in the G2/M phase in NB cells. 
Fig 19: TMZ does not alter galectin-1 expression after knockdown by siRNA in NXS2 
and SK-N-BE(2) cells. 1.5 x 105 NB cells were transfected with anti-galectin-1 sRNA 
(gal-1 si) or unrelated scrambled siRNA (scr si) in six welled plates. After 24 hours, 
the cells were treated with 100 µM TMZ or 0.1 % DMSO (DM) vehicle control or left 
untreated (NT) for 72 h. Protein extracts were then subjected to western analysis. 
Blots were probed with galectin-1 antibody and later striped and re-probed with anti 
GAPDH antibody as a loading control.  
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Fig 20: Galectin-1 knockdown does not change the cell cycle 
distribution of NB cells. SK-N-BE(2) (A)  and NXS2 (B) cells were 
treated as in Fig 28 and cell cycle analysis were performed by 
FACS. Error bars are from three independent experiments. 
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3.8. Steps towards an orthotopic neuroblastoma tumour model 
The primary objective was to establish an orthotopic syngeneic NB mouse model 
presenting disseminated NB in different organs typical of NB metastasis. For this 
purpose a tumour induced by NXS2 cells in A/J mouse was excised, cut into 
pieces of approximately 1 mm3 and surgically placed on the adrenal gland of a 
second A/J mouse (see 2.3.2). After 28 days, the mice were killed and the organs 
were examined for macroscopic metastases. Hematoxylin-eosin (HE) stained 
tissue sections from the spleen, kidney and liver were also examined for 
micrometastases. Although all mice developed tumours at the surgical site, no 
apparent organ metastases were observed at autopsy (Fig 21). Lack of micro 
metastases was also confirmed by HE staining (Fig 22).  
Fig 21: Macroscopic examination of mouse organs. NXS2 NB cells were 
injected into the left adrenal gland of AJ mice. Photomicrographs were taken 
at autopsy of different organs including tumour. A) contra-lateral adrenal gland 
and kidney. B) Tumour sandwiched between the liver and kidney of injected 
adrenal gland. 
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Fig 22: Microscopic examination of mouse organs and tumour. Microscopic 
examination of HE stained tissue sections reveal no micro metastasis. Tumour 
sample was also stained for comparison (positive control). 
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3.9. FTS does not show anti-tumour activity as a single agent but 
chemosensitises experimental NB to the effects of TMZ 
Although NB cells displayed only modest sensitivity to FTS and TMZ in vitro, other 
reports have shown their therapeutic benefit in vivo (Le Mercier et al., 2007). 
Hence, the therapeutic potential of single agent FTS as well as its sensitising 
effect in combination with TMZ was investigated in a NB syngeneic model.  AJ 
mice (n = 6/group) were injected subcutaneously with NXS2 NB cells and treated 
with 20 mg/kg FTS (i.p.)  alone or 40 mg/Kg TMZ (i.p.) alone every other day, or 
as combination therapy with single agents administered individually on alternate 
days (Fig 23). Mice were sacrificed when tumour volume reached 1000 mm3 
(primary endpoint) or appeared sickly. FTS did not significantly increase the 
survival of tumour-bearing mice compared to control group (P = 0.93) whereas 
TMZ significantly improved the survival of animals when compared to controls (P = 
0.03). However the combination of FTS and TMZ neither did not significantly 
improve the therapeutic benefits of TMZ alone (P = 0.51) nor the survival of mice-
bearing tumours when compared with controls (P = 0.05). It should however be 
emphasised that this experiment was stopped due to treatment related side 
effects. Hence, the results presented are preliminary, but suggest a “synergistic” 
effect of FTS and TMZ may exist. At that time, only one out of the six mice of the 
group receiving the combination treatment but all of the mice in the control and 
FTS single agent groups had reached the primary endpoint.  
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Fig 23: Kaplan Meier survival analysis for the evaluation of NB growth inhibition by 
FTS and TMZ in a NB syngeneic model. AJ mice were injected s.c. on the lower 
left flank with 5.0 x 106 NXS2 cells and were treated i.p. with either 20 mg/kg FTS 
(green) or 40 mg/kg TMZ (red) alone every other day or a combination of both 
drugs (blue) on alternating days until the experiment was stopped. Control group 
received PBS/5 % DMSO (black). Treatment was initiated one day after 
inoculation.  
P = 0.0296 
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3.10. TMZ or galectin-1 downregulation increase the survival of NB tumour 
bearing mice but do not act synegistically 
Decreasing galectin-1 expression in a mouse melanoma and glioma models have 
been shown to improve the anti-tumour effects of TMZ (Mathieu et al, 2007; Le 
Mercier et al., 2008). Thus the potential of galectin-1 to inhibit tumour growth and 
to sensitise to treatment with TMZ was examined in a NB xenograft model. SK-N-
BE(2) cells were transfected with either siRNA directed against galectin-1 or an 
unrelated scrambled siRNA and grafted s.c. to groups of nu/nu mice (n=6) after 
eight days. Western analysis confirmed depletion of galectin-1 expression (see Fig 
5) compared to untransfected or scrambled siRNA transfected cells. TMZ (40 
mg/kg) was then administered i.p. to two groups of mice (one grafted with gal-1 
siRNA transfected cells and the other with scrambled siRNA) three times a week 
for four weeks one day after tumour grafting. Two groups received 5% DMSO in 
PBS as per TMZ treatment. As seen in Fig 24, decreasing galectin-1 expression 
alone and TMZ treatment alone significantly increased the survival of tumour-
bearing mice when compared to scrambled siRNA plus vehicle control group (P = 
0.0069 and P = 0.0037 respectively). However galectin-1 depletion plus TMZ 
treatment did not result in any additive beneficial effect to the survival of scrambled 
siRNA plus TMZ treated group (P = 0.0037). These results imply that galectin-1 
reduces tumour burden as effective as TMZ but no additive effects to TMZ anti-
tumour activity in this NB model. 
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Fig 24: Effect of decreasing Galectin-1 silencing and response to TMZ in NB 
xenograft model. 8 – 10 weeks old nu/nu mice were grafted with 1.0 x 107 SK-N-
BE(2) cells transfected with either gal-1 siRNA and treated with vehicle control 
(red line) or TMZ (blue line) or transfected with scrambled siRNA and then  
treated with vehicle control (black line) or TMZ (green line). TMZ administration 
began one day post tumour grafting to mice at 40 mg/Kg i.p. three times a week 
for four weeks. As vehicle control, 5 % DMSO in PBS was used. Mice were 
sacrificed when tumour volume had reached 1000 mm3. Scr+TMZ Vs gal-1+TMZ 
groups show no significant difference (log rank test, P = 0.7710). 
P = 0.006 
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3.11. The tumour growth inhibitory effect of TMZ and galectin-1 silencing is 
not primarily caused by reduced cell proliferation  
To determine the mechanism that contributes to the tumour growth inhibition 
following transient galectin-1 knockdown or treatment with TMZ, ki67 staining was 
performed using fixed tissue sections from SK-N-BE(2) tumours in all treatment 
groups. As shown in Fig 25 (a) and (b), neither TMZ treatment nor galectin-1 
silencing resulted in reduced proliferation when compared to control and 
scrambled siRNA control groups. Combined TMZ plus galectin-1 knockdown did 
not result in any change in proliferation compared to scrambled siRNA plus TMZ 
treated groups. 
Fig 25(a): TMZ and Gal-1 silencing anti-tumoural effects are not due to 
proliferation inhibition in NB mouse xenograft model. Histological sections were 
obtained from the tumours of the mice in each treatment group. Representative 
sections from each treatment group are shown. A) scr + control, B) scr + TMZ; C) 
gal-1 + control; D) gal-1 + TMZ  
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Fig 25 (b): TMZ and gal-1 silencing does not reduce Ki67 proliferation index 
in the SK-N-BE(2) NB xenograft model. Histological sections were obtained 
from the tumours of the mice in each treatment group and Ki67 staining was 
performed. Average proliferation index of each treatment group was 
determined by counting positive cells per microscopic field at 100 x 
magnification. No significant difference in the proliferative index (% of Ki-67 
positive cells) was found for the treatment groups (e.g. Scr+ TMZ versus 
gal-1 + TMZ, P = 0.3812). 
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4 DISCUSSION 
Galectin-1 has been shown to be implicated in different aspects of tumour biology, 
including angiogenesis, invasiveness and tumour immune escape in many 
tumours (Rabinovich et al., 2005, Camby et al., 2006). We have previously shown 
that galectin-1 mRNA and protein levels are up-regulated in patients with the 
aggressive subtype of NB (Schramm et al, 2005, Sitek et al., 2005). Furthermore, 
galectin-1 blockade in tumour cells has been demonstrated to halt tumour 
progression (Rubenstein et al., 2007) and also to potentiate the effects of the pro-
autophagic drug TMZ (Mathieu et al., 2007). In this study, the effects of galectin-1 
loss were elucidated both in vitro and in vivo to evaluate blocking galectin-1 
functions as a treatment for aggressive NB.  Here we used the well characterised 
human NB cell lines Kelly (Schwab et al., 1983) and SK-N-BE(2) and also the 
murine NB cell line NXS2 (Lode et al., 1997) which reflect the more aggressive 
forms of NB. 
Various obstacles exist for the development of therapies for paediatric cancers. 
The rarity of these diseases is a considerable problem. Neuroblastoma is the most 
common extracranial paediatric solid tumour, yet only 150 children and 
adolescents will be diagnosed each year in Germany (Deutsches Kinderkrebsre-
gister, Jahresbericht 2007). This is in sharp contrast to the most common adult 
solid tumour, lung cancer, with more than 50,000 new cases diagnosed annually 
(Robert Koch Institut, Verbreitung von Krebserkrankungen in Deutschland 
2010). With so few people affected by this disease, there is a reduced market 
incentive for industry-based drug development. A second challenge, even with 
drug in hand, is the development of clinical trials adequately powered to address 
the question of efficacy. Testing combinations of compounds adds yet another 
layer of complexity. When only a limited number of drugs can be tested, rational 
selection for testing becomes critical. Thus the need for mouse models in 
evaluating new combination therapies is an invaluable asset.  
 
Current regimens for high-risk neuroblastoma cure fewer than half of all patients, 
with many experiencing relapse from minimal residual disease remaining after 
consolidation with high-dose chemotherapy and autologous hematopoietic stem-
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cell transplantation (Matthay et al., 1999). Although some success has been 
achieved using post-transplantation maintenance therapy with the differentiating 
agent 13-cis-retinoic acid or with monoclonal antibodies targeting neuroblastoma-
specific proteins (Cheung et al., 1998), further advances are needed. Also, it is 
becoming increasingly evident that conventional chemotherapeutics are 
approaching or perhaps have already attained their maximum therapeutic 
potential. Thus, novel therapeutic options are warranted. 
In this study, the antitumoural efficacy of TMZ and FTS, both novel therapies, were 
tested in NB models. 
 
4.1. In vitro studies 
Three methods were used in order to down-regulate galectin-1 expression i.e. 
RNAi or chemical inhibition using HDACi. Though siRNA successfully decreased 
galectin-1 expression in all cell lines tested, we could not develop a stable 
galectin-1 stably transfected shRNA cell NB cell line since the cells reach 
senescence after about eight weeks of selection. Both the cells with the plasmid 
construct and empty vector attained senescence at the same time suggesting that 
the problem could be the vector hence a different construct using a different vector 
can be used instead.  
Galectin-1 transient silencing induced growth arrest in all NB cells lines indicating 
that gal-1 plays a regulatory role on cell proliferation in NB. However the 
mechanisms of this anti-proliferative activity still requires elucidation. FACS 
analysis of the different cell cycle distribution after galectin-1 depletion did not 
show any changes to untransfected cells. This is in contrast to what is observed in 
colorectal cancer where intracellular gal-1 induces cell cycle arrest and apoptosis 
(Sateli & Rao, 2010). Ironically, reduced expression of galectin-1 expression in 
both glioma (Le Mercier et al., 2008b) and Melanoma (Mathieu et al., 2007) did not 
result in any apoptosis or autophagy. These variable results emphasise the 
delicate role galectin-1 plays in different tumour types and also suggest that the 
mechanism of galectin-1 induced antitumour effects are tumour or cell type 
specific. 
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4.2. HDAC Inhibitors and Galectin-1 Silencing 
The pharmacologic inhibition of histone deacetylases (HDAC) is an emerging 
novel molecular treatment strategy in cancer therapy (reviewed in Yoo & Jones, 
2006; Menucci & Pelluci, 2006). HDAC inhibitors have been shown to induce the 
inhibition of cell growth, migration, apoptosis, and to promote differentiation in 
several cancer cell lines in vitro, and to exert antitumoural effects in mouse models 
(Marks et al, 2001; Bolden et al., 2006; Furchert et al., 2007; reviewed Pan et al, 
2007). In NB, HDACi have been demonstrated to suppress many tumour-relevant 
proteins e.g. MYCN, survivin, E2F-1, all of which are found up-regulated in 
aggressive, high-risk NB (Deubzer et al., 2008). In other studies, inhibitors of 
HDAC were reported to restore p53 tumour suppressor pathway by increasing 
p21Waf1/Cip1 and activating p53 gene (Condorelli et al., 2008). As a functional 
consequence, HDACi induce growth inhibition and cell arrest in cultured cells 
(Toscani et al, 1998; Deubzer et al, 2008). Galectin-1 is negatively regulated by 
p53 (Puchades et al., 2007; Le Mercier et al., 2008a) and Gal-1 reciprocally has 
been shown to modify p53 biological functions and increase p21Waf1/Cip1 in human 
glioblastoma. In addition, galectin-1 has been previously been associated with NB 
cell migration and invasion (Cimmino et al., 2009). We therefore tested the 
hypothesis that HDACi might also down-regulate galectin-1 expression in NB cells. 
Functionally, HDACi treatment inhibited cell proliferation, which is an unexpected 
finding given the previous findings linking galectin-1 expression to a more 
aggressive NB phenotype. The mechanisms of galectin-1 modulation by HDACi 
remain unclear. This notwithstanding, this result points to the specific actions of 
HDACi in transcriptional regulation of gal-1 and indirectly supports the contention 
that galectin-1 expression is linked to the status of histone acetylation. Moreover, 
this was the motivation to explore a synergistic effect of down-regulating galectin-1 
in combination with HDACi. 
It turned out that siRNA-mediated galectin-1 downregulation sensitized only SK-N-
BE(2) NB cells to the anti-proliferative activity of SAHA but not to VPA in vitro as 
monitored by real time viability analyses (XCelligence, Roche). This phenomenon 
is not observed using the MTT assay, which did not reveal synergy of galectin-1 
depletion and HDACi on NB growth inhibition. Whether these results are due to 
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the fact that the MTT assay is an endpoint measurement recording only 
mitochondrial activity at a given time, whereas the xcelligence “Cell Index” 
monitors cellular attachment and viability in real-time, remains to be determined. 
Interestingly, galectin-1 knockdown apparently potentiates the cytotoxic effects of 
VPA in NXS2 cells but not in Kelly and SK-N-BE(2) cells. This discrepancy might 
be due to the fact that cell lines are as heterogeneous as the tumours they 
originate from thus affecting the clinical outcome of different treatment schedules 
(George et al., 2010). However, these findings however illustrate that a 
combination of gal-1 blockade and HDACi could be a valuable treatment option in 
NB and therefore merits further investigation in vivo to fully establish its efficacy. 
 
4.3. TMZ , FTS and Galectin-1 Silencing in vitro and in vivo 
Since many of the functions of galectin-1, such as tumour invasiveness or 
angiogenesis, can be best assessed in a model reflecting the full metastatic 
capacity, we also aimed to establish an orthotopic model of NB by microsurgery. 
This NB model should mimic disseminated or relapsing NB and combine the 
benefits of both orthotopic (intra-adrenal injection of NB cells) and syngeneic (use 
of murine cell line, NXS2) model potentials to improve the power that illustrates a 
true clinical situation. Mice developed tumours but the absence of both macro and 
micro metastasis meant the model was not suitable for its intended use. A 
plausible explanation of this might be that the amount of cells injected in the 
adrenal gland was not sufficient to elicit metastasis. Also, there is the possibility 
that most of the cells injected in the adrenal gland were extruded into the 
interstitial space due to high pressure from within the adrenal. A good way of 
improving intra-adrenal intake will be to mix cell suspension with 
fibrinogen/thrombin for clot formation thus preventing extrusion of cells after 
injection. The protocol/procedure used in the development of this syngeneic 
orthotopic model is a promising one since the surgical procedure and tumour 
development was successful. It should be well noted that this is still a model in 
building as work is still going on to improve several technical aspects e.g. tagging 
cells with luciferase and use of MRI  to monitor cell growth in life time.  
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TMZ is a pro-autophagic (Kanazawa et al., 2004) and pro-angiogenic (Kurzen et 
al., 2003; Fischer et al., 2007) drug that has demonstrated anti-tumour activity in a 
number of tumour types including paediatric tumours. It has also shown anti-
tumour activity against preclinical NB mouse models (Middlemas et al., 2000; 
Houghton et al., 2000; Wagner et al., 2007) and has now been tested in clinical 
trials for children with high-risk relapsing NB (Wagner et al., 2010; Rubie et al., 
2006) hence illustrating its power in NB therapy. Furthermore, stable as well as 
transient galectin-1 downregulation have been reported to sensitize tumour cells to 
the effects of TMZ in both melanoma and Glioma models (Mathieu et al, 2007; Le 
Mercier et al., 2008a; Le Mercier et al., 2008b). With these features in mind, we 
studied the effect of gal-1 knockdown and treatment with TMZ in NB model 
systems. It has been previously shown that TMZ increases the expression of gal-1 
in gliomas (Mathieu et al., 2007; Le Mercier et al., 2008b). Interestingly, TMZ 
apparently does not alter the expression of gal-1 in NB cells both at the mRNA and 
protein levels suggesting that TMZ does modulate gal-1 expression in NB. 
Our data show that TMZ (100 µM) does have weak cytotoxic effect against all NB 
cell lines tested in vitro. This result is consistent with the other reports in 
melanoma and glioblastoma (GBM). TMZ is known to induce G2/M growth arrest 
in tumour cells (Kanazawa et al., 2004). In the present study, TMZ induced only a 
modest shift of the cell cycle to G2/M growth arrest, which was not statistically 
significant. These results laid the foundation to evaluate the in vivo effects of 
combining TMZ and galectin-1 downregulation (see below). 
FTS is a Ras antagonist that prevents the attachment of Ras to the cell membrane 
leading to its degradation by disrupting the Hras/gal-1 association (Paz et al., 
2001). We therefore assessed the effect of FTS on NB cells in culture. FTS did not 
inhibit growth of the human NB cells tested but was cytotoxic to the murine NB cell 
line NXS2. A plausible explanation for this might be that, certain genetic factors 
inherent in the murine cell line render them susceptible to FTS. This observation in 
human NB cells is inconsistent with the well established growth inhibitory effect of 
FTS to other tumour types like glioblastoma (Blum et al., 2006; Amos et al., 2006), 
Melanoma (Smalley & Eisen, 2002), Prostate cancer (Mcpherson et al, 2003) and 
Lung cancer (Zundelevich et al., 2007). Taken into consideration the action of FTS 
on activated Ras and also that these tumours either harbour mutated or activated 
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Ras, one might be tempted to conclude that FTS is effective only in those tumours 
in which Ras is essential as a driving. This is further supported by the report that 
FTS disrupts the interaction between Ras and MYCN leading to reduced 
expression of both proteins and inhibiting growth of LAN-1 NB cells in vitro. LAN-1 
in this study expressed very high amounts of MYCN and active Ras (Yaari et al., 
2005). Since the action of FTS also strongly depends on the association of HRas 
and gal-1, the interaction of gal-1 and HRas was assessed. Our results show that 
gal-1 interacts with HRas and that FTS treatment of NB cells does not result in any 
significant expression in gal-1 expression. However a study of the interaction of 
activated HRas and gal-1 will shed more light as to the actions of FTS in NB. 
Again FTS alone did not induce any changes in the cell cycle distribution of all cell 
lines tested indicating that reduced proliferation of NXS2 cells by FTS is not as a 
result of cell cycle growth arrest. 
In addition to the set of mechanisms already identified for FTS antitumour 
activities, the compound also exerts its effect by impairing angiogenic processes 
(Blum et al., 2005). Also, FTS sensitized melanoma cells in vivo to the 
antitumoural effects of Dacarbazine (Halaschek-Wiener et al., 2003). Owing to the 
fact that TMZ is an imidazotetrazine derivative of Dacarbzine, we hypothesized 
that FTS will also sensitise NB cells to the antitumour effects of TMZ. This 
hypothesis was tested in a NB mouse syngeneic model since NXS2 cells had 
already shown tumour growth inhibitory activity in vitro. Despite the weak cytotoxic 
effect of TMZ in vitro, it did significantly increase the survival of tumour-bearing 
mice. When tumours were treated with TMZ and FTS, the combined effect was not 
different from TMZ monotherapy. Combination therapy did not show any improved 
effectiveness in localised tumours resulting in no relative improved survival of mice 
bearing tumours compared to TMZ alone treated group. Only functional assays of 
NXS2 FTS treated cells can provide hard evidence for this scenario. Bearing in 
mind the considerable role TrkB plays in NB aggressiveness (Kohl et al., 1984), in 
activating Ras and our previous finding of gal-1 involvement in TrkB mediated NB 
aggressiveness, one can suggest that studies of the interplay of these factors 
might be beneficial in understanding the effects of FTS in NB. 
Furthermore, we analysed the consequences of galectin-1 knockdown and its 
power to sensitize NB tumours to the growth inhibitory effect of TMZ in a NB 
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xenograft model, as this has been found to be the most reproducible system in 
terms of tumour growth and comparability of response parameters. Transient 
galectin-1 downregulation by siRNA significantly increased the survival of tumour 
bearing mice as effective as TMZ. However, gal-1 depletion did not improve the 
survival of tumour bearing mice when treated with TMZ. This result also contrasts 
what has been described for experimental melanoma and glioblastoma. 
Additionally, TMZ treatment alone or galectin-1 knockdown was not able to reduce 
the Ki67 index possibly negating the anti-proliferative role of both gal-1 
downregulation and TMZ to be the mechanism of action in tumour growth 
inhibition in NB. Again, the fact that TMZ increases the expression of gal-1, a 
phenomenon not observed in the present study, suggest that TMZ might work 
completely differently in NB. 
All in all, the data strongly reinforce the therapeutic potential of galectin-1 loss in 
NB and also supports the use of TMZ as chemotherapeutic treatment for NB. 
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5. Conclusion 
High-risk NB is a difficult disease to treat and relapsing minimal residual disease is 
generally resistant to current therapeutic regiments. Overexpression of galectin-1 
can be one mechanism by which NB become resistant to chemotherapeutics since 
its overexpression correlates with aggressiveness of the disease. 
In the present study, we first showed that downregulation of galectin-1 resulted in 
a decreased viability of NB cells in vitro. The potential therapeutic effects of 
depleting galectin-1 were then demonstrated in an in vivo NB model. Decreasing 
the expression of galectin-1 in an NB experimental model reduced tumour burden 
and prolonged the survival of mice-bearing tumours. 
Furthermore, the therapeutic potential of both farnesyl-thiosalicylate (FTS) and 
temozolomide (TMZ) were elucidated. While FTS did not show antitumoral activity 
except for one NB murine cell line, NXS2, in vitro and in vivo, TMZ was effective in 
inhibiting growth of NB tumours. 
There was no synergistic effect of combining TMZ and FTS or of silencing 
galectin-1 and treatment with either FTS or TMZ. Further studies on the 
mechanisms, by which galectin-1 loss causes tumour growth inhibition may result 
in the design of more effective targeted therapy regimens for NB. For example, 
gene expression profiling of galectin-1 knockdown in NB cell lines might reveal 
genes involved in pathways responsible for galectin-1 mediated tumour 
progression and aggressiveness in NB. 
Most importantly, this study has shown that interfering with galectin-1 function 
impairs tumour growth in all NB models analysed. Since galectin-1 is expressed in 
all primary NBs and also in gliomas, melanomas and other tumour entities, our 
conclusion is that galectin-1 is a bona fide cancer target. Galectin-1 
downregulation therefore provides an excellent tool for new treatment strategies in 
children with high-risk NB. 
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